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ABSTRACT 
Içten, Elçin. Ph.D., Purdue University, May 2016. Manufacture of Individualized Dosing: 
Development and Control of a Dropwise Additive Manufacturing Process for Melt Based 
Pharmaceutical Products. Major Professors: Zoltan K. Nagy and Gintaras V. Reklaitis. 
 
 
The improvements in healthcare systems and the advent of precision medicine initiative 
have created the need to develop more innovative manufacturing methods for the delivery 
of individualized dosing and personalized treatments. In recent years, the US Food and 
Drug Administration (FDA) introduced the Quality by Design (QbD) and Process 
Analytical Technology (PAT) guidelines to encourage innovation and efficiency in 
pharmaceutical development, manufacturing and quality assurance. As a result of 
emerging technologies and encouragement from the regulatory authorities, the 
pharmaceutical industry has begun to develop more efficient production systems with 
more intensive use of on-line measurement and sensing, real time quality control and 
process control tools, which offer the potential for reduced variability, increased 
flexibility and efficiency, and improved product quality. 
 
In accordance with the changes observed in health care systems towards more innovative 
personalized therapies, this dissertation presents a novel technology for small scale, 
distributed manufacturing of individualized dosing. A dropwise additive manufacturing 
process for melt-based solid oral drug production is developed, which utilizes the drop-
xxiii 
 
on-demand (DoD) printing technology for predictable and highly controllable deposition 
of active pharmaceutical ingredients (API) onto an edible substrate, such as a polymeric 
film or placebo tablet. This manufacturing method has tremendous potential in 
individualized dosing because through a combination of drop size and number of drops, 
the dosage can be precisely and reliably controlled to match the prescribed amount for a 
patient. 
 
The real-time process management (RTPM) strategy is developed for the dropwise 
additive manufacturing of pharmaceutical products (DAMPP). The automation program 
assures synchronous operation of process units, while monitoring process parameters and 
maintaining process control. The automation program is integrated with the Knowledge 
Provenance Management System (KProMS) to record and make accessible the data 
provenance of each and every dosage produced via DAMPP.  
 
For the dropwise additive manufacturing system, the critical process parameters (CPP) 
are controlled to achieve the desired critical quality attributes (CQA) of the dosage forms. 
The effect of the CPPs on the final drug property is investigated and it is shown that 
implementation of a supervisory control system on the process is essential for producing 
individual dosage forms with the desired CQAs. A polynomial chaos expansion based 
surrogate model is developed to predict the dissolution profile of the solidified drug 
deposition given the temperature profile applied on the substrate. Using this model, a 
hierarchical control system is implemented by monitoring the drop size on-line and 
predicting a temperature profile to achieve the desired dissolution profile for the dosage 
xxiv 
 
forms created. The process control strategy effectively mitigates variations in the 
dissolution profiles due to variable dosage amounts, hence enabling the application of the 
DoD system for the production of individualized dosage regimens. 
 
A crystallization model based on non-isothermal Avrami kinetic equation is developed 
for the cooling temperature dependent solid-state transformation of the melt-based solid 
oral dosages produced using the dropwise additive manufacturing process. This model 
increases the understanding of solidification and crystallization processes from 
undercooled melts. Using the proposed model, the effect of temperature profiles leading 
to differences in solid-state parameters such as the mean size can be investigated. 
 
The DAMPP process is a viable method for on-demand production of various 
formulations. Melt-based dosage forms containing crystalline API and self-emulsifying 
drug delivery systems with amorphous API forms are produced and analyzed to 
demonstrate reproducibility of dosages and their dissolution behaviors. 
 
The prototype system offers great promise as a tool for advancing personalized medicine 
by allowing the precise production of convenient solid oral dosages tailored to the patient 
on site at hospitals, clinics and even pharmacies. Future directions are suggested to 
further advance dropwise additive manufacturing of pharmaceutical products and lead to 
commercialization of this technology. 
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 INTRODUCTION CHAPTER 1.
1.1 Introduction 
The average life expectancy has increased dramatically during the 20th century. The 
ceaseless improvement in human health care systems consisting of the development of 
new treatments and the increasing accessibility to medicine has a significant effect on this 
achievement. Nevertheless, medicine still targets therapy to the broadest patient 
population that might possibly benefit from it, and it relies on statistical analysis of this 
population's response for predicting therapeutic outcome in individual patients [1].  
Therapists make decisions both about the choice of drug and appropriate dosage based on 
information derived from population averages. Worldwide use of these drugs has 
revealed substantial interindividual differences in therapeutic response [1]. With the 
recent developments in pharmacology and genomics, this "one drug fits all" approach is 
evolving into a personalized approach to therapy [1]–[3]. It is paving the way towards 
future health care systems, which was also recently announced in the precision medicine 
initiative [4]. Personalized therapy is defined as therapy with the right drug at the right 
dose for the right patient, which implies the delivery of personalized medicine and 
individualized dosing [1]–[3], [5]. 
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As health care systems keep improving not only discovery of new drugs and therapies but 
also development of innovative drug delivery and production methods become crucial. 
The current level of innovation in dosage form design and drug product manufacturing 
cannot meet the needs of personalized therapies [6]. While innovation is the key to 
success within the pharmaceutical industry, it has been largely sought through new drug 
discovery and development, while the development of new manufacturing methods has 
received inadequate attention. Traditionally the pharmaceutical industry has 
manufactured its products in large scale batch processes with nonexistent or limited on-
line process monitoring and control. In recent years, the US Food and Drug 
Administration (FDA) introduced the Quality by Design (QbD) approach and Process 
Analytical Technology (PAT) guidance to encourage innovation and efficiency in 
pharmaceutical development, manufacturing and quality assurance [7]. As a result of 
encouragement from the regulatory authorities, the advent of globalization and the 
increasing awareness of environmental impact, the pharmaceutical industry has been 
reconsidering the way drug products are developed and manufactured [8], [9].  
 
Thus, in accordance with the changes observed in health care systems towards more 
innovative personalized therapies, this dissertation focuses on the manufacture of 
individualized dosing by developing a dropwise additive manufacturing process for melt-
based solid oral drug production. A novel manufacturing technology based on drop-on-
demand printing is presented for small scale, distributed manufacturing of drug dosage, 
which enables cost-effective production of individualized dosing. This manufacturing 
method has tremendous potential in individualized dosing because through a combination 
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of drop size and number of drops, the dosage can be precisely and reliably controlled to 
match the prescribed amount for a patient. In addition, the ‘batch size’ can be as small as 
the number of tablets or drops required for one patient and the transitions from one dose 
to another made with minimal or no waste in very short time.  The dropwise additive 
manufacturing system offers great promise as a tool for advancing personalized therapies 
by allowing the precise production of convenient solid oral dosages tailored to the patient 
on site at hospitals, clinics and even pharmacies. 
 
1.2 Project Motivation 
Accessibility to medicine designed for exclusive therapeutic needs of individual patients 
will be a tremendous achievement for the healthcare system. The research project aims to 
solve the challenge of manufacture of individualized dosing by the development and 
control of a dropwise additive manufacturing process for pharmaceutical products 
(DAMPP). As a part of the National Science Foundation supported Engineering Research 
Center for Structured Organic Particulate System (C-SOPS), a prototype system for 
DAMPP is developed, which uses the drop on demand (DoD) technology. The main 
advantages of using DoD technology for drug printing are the ability to produce small 
droplets of controlled sizes and to produce these drops with high placement accuracy 
onto selected substrates [10]. By changing the drop size and the composition of the 
formulation, the dosage amount can be tailored according to the patient’s needs.  
 
C-SOPS focuses on advancing the scientific foundation and developing methodologies 
for the active control and manufacturing of pharmaceutical products and brings together a 
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multi-disciplinary team of engineers, scientists and industry leaders to improve 
pharmaceutical production processes [11]. C-SOPS supports the development of three 
test beds, which are TB1: Continuous Manufacturing of Tablets, TB2: Strip Films for 
Controlled Substance Delivery and TB3: Mini-Manufacturing using Drop-on-Demand 
Technology. The DAMPP process corresponds to TB3. 
 
1.3 Research Objectives 
The major focus of the research work is the development of the dropwise additive 
manufacturing process for pharmaceutical products. The advancement of the system to 
process melt-based dosage forms requires an assembly of various scientific and 
engineering principles including drop dynamics, heat transfer, automation, process 
control, data management, process analytics and pharmaceutical sciences. Here, a real 
time process management strategy is crucial to enable the application of this system for 
the production of dosage forms with the desired quality attributes matching 
individualized dosage regimens. Establishing automation and process control of the 
system, monitoring important process parameters online and managing process data are 
essential elements of a meticulous real time process management strategy. While 
developing a process to manufacture pharmaceutical dosage forms, the process 
parameters should be precisely controlled to reach the final product quality attributes. 
Therefore important quality attributes need to be identified and their relationship to 
quality attributes need to be modelled. Another objective is to demonstrate that the 
process can utilize various pharmaceutical formulations and to characterize the resulting 
dosage forms with various methods. 
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1.4 Thesis Overview 
Chapter 2 presents dropwise additive manufacturing of pharmaceutical products for melt-
based dosage forms. This chapter discusses the rationale for developing the drop-on-
demand process for pharmaceutical applications and implementation of the DoD system 
for different pharmaceutical formulations with an emphasis on melt-based drug systems. 
 
Chapter 3 describes the real time process management (RTPM) strategy developed for 
dropwise additive manufacturing of pharmaceutical products. The RTPM strategy 
consists of automation, online monitoring and process control. It is successful in 
controlling deposition of either solvent-based or melt-based dosage forms and ensures 
that every dosage unit meets quality specifications. It controls process and product 
temperature and monitors each drop visually. It records data pertinent to each deposited 
drop, determines the drop volume and thus API amount deposited, and conducts analyses 
that can detect process faults. 
 
Chapter 4 presents a workflow based knowledge provenance management system, 
KProMS, developed for DAMPP. DAMPP requires and generates a range of data types, 
including camera and IR images, spectra and numerical parameter values, both of real 
time and off-line nature. KProMS is integrated with the automation program and captures 
relationships between the processing steps and material and information flows, and data 
input and output generated by DAMPP. Thus a complete data provenance is recorded for 
each dose produced. 
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In Chapter 5, a supervisory control system is presented, that is designed to ensure 
reproducible production of high quality of melt-based solid oral dosages. This control 
system enables the production of individual dosage forms with the desired critical quality 
attributes by monitoring and controlling critical process parameters. The effects of these 
process parameters on the final product quality are investigated and the properties of the 
produced dosage forms are characterized using various techniques. 
 
Chapter 6 describes a process control framework for DAMPP to produce individual 
dosage forms with the desired critical quality attributes, including formulation 
composition, drop size, deposit morphology and dissolution performance. In order to 
achieve desired product morphology, a surrogate model based on polynomial chaos 
expansion is developed to relate the critical process parameters to deposit morphology 
using dissolution data of the active pharmaceutical ingredient. The proposed process 
control strategy can effectively mitigate variations in the dissolution profiles due to 
variable dosage amounts and enable the application of the DoD system for the production 
of individualized dosage regimens. 
 
In Chapter 7, a model based on non-isothermal Avrami kinetic equation is developed to 
model the solidification and crystallization processes of the drug deposits under different 
cooling profiles using temperature dependent crystallization kinetics. Using the proposed 
model, the temperature profiles leading to the desired solid-state parameters such as the 
minimum mean size are determined.  
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In Chapter 8, dropwise additive manufacturing of amorphous and self-emulsifying melt-
based solid oral dosage forms is demonstrated for improved oral delivery of lipophilic 
drugs. Different lipid carriers are investigated to increase the bioavailability of poorly 
water soluble drugs. The produced dosage forms are analyzed with various techniques.  
 
Chapter 9 talks about future directions and suggested studies to further advance the drop 
on demand manufacturing system. 
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  DROPWISE ADDITIVE MANUFACTURING PROCESS FOR MELT CHAPTER 2.
BASED PHARMACEUTICAL PRODUCTS* 
2.1 Introduction 
The large-scale batch processing mode which the pharmaceutical industry has 
traditionally used to manufacture pharmaceutical products provides significant challenges, 
including high production costs, long manufacturing times, scale-up difficulties and 
recurring quality issues [12]. The increasing competition and payer pressures are driving 
the pharmaceutical industry to deliver drug products in shorter time and lower cost [13]. 
The US Food and Drug Administration (FDA) has promoted the Quality by Design (QbD) 
approach to increase process understanding and improve quality and efficiency while 
minimizing risk [14]. The Process Analytical Technology (PAT) guidance introduced by 
the FDA encouraged the monitoring of critical quality and performance attributes during 
processing with the goal of ensuring final product quality [7], [15]. 
 
As part of this renewed emphasis on improvement of manufacturing, the pharmaceutical 
industry has begun to shift towards continuous processing and to develop more efficient 
production systems with more intensive use of on-line measurement and sensing, real
                                                 
* This chapter is based on: E. Içten, A. Giridhar, L. S. Taylor, Z. K. Nagy, and G. V 
Reklaitis, “Dropwise Additive Manufacturing of Pharmaceutical Products for Melt-Based 
Dosage Forms.,” Journal of Pharmaceutical Sciences, vol. 104, no. 5, pp. 1641–1649, 
2015[19].  
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time quality control and process control tools, which offer the potential for reduced
production costs, faster product release, reduced variability, increased flexibility and 
efficiency, and improved product quality [13], [16], [17]. 
 
This chapter presents a dropwise additive manufacturing process for pharmaceutical 
products (DAMPP) as an alternative to conventional methods. The process utilizes the 
drop-on-demand (DoD) printing technology for predictable and highly controllable 
deposition of active pharmaceutical ingredients (API) onto an edible substrate, such as a 
polymeric film or placebo tablet [18], [19]. This process uses fluid operations suitable for 
low volume production of personalized dosage forms.  
 
The main advantages of using DoD technology for drug printing are the ability to 
produce small droplets of controlled sizes and to produce these drops with high 
placement accuracy onto selected substrates [10]. The advantages of liquid processing 
and reproducible production of small droplets create the special opportunity for the 
production of high potency, low dose drugs, which are difficult to produce with 
consistent quality via conventional powder processing methods. By changing the drop 
size and the composition of the formulation, the dosage amount can be adjusted 
according to the patient’s needs. The ability to adjust the dosage amount according to 
patient’s needs and layering of multiple drugs enable the process to produce 
individualized dosage products. For most drugs, a “one dose fits all” or standardized 
dosage regimen is recommended for patients regardless of their age, sex, or other 
physiologic factors [20]. Standardized dosing is preferred because it simplifies the 
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production/packaging processes, the associated product supply chain and the prescription 
of the drug by physicians [21].  
 
However, given that interpatient variability in pharmacologic response can be large due 
to pharmacokinetic (PK) and pharmacodynamics (PD) differences, a “one dose fits all” 
approach may result in ineffective or excessive dosing [21]. Any given drug can be 
therapeutic in some individuals but ineffective in others, and some individuals experience 
adverse drug effects whereas others are unaffected [1]. It has been reported that 
optimization-based methods, which use PK-PD models with parameter distributions 
determined from population clinical data together with a limited number of plasma 
samples from a specific patient, can effectively predict a regimen that has the highest 
probability of meeting the therapeutic needs of that patient [22]. Thus the dosage regimen 
can be individualized to the patient and the DAMPP process can be employed to produce 
that predicted dose in a clinic or a pharmacy. This would change the supply chain 
structure of the industry from mass production of multiple dosages for each drug to bulk 
production of the formulation for that drug with the actual dosage produced on demand at 
distributed sites. Of course, the DoD technology can also be employed for commercial 
scale production of drug products, as is the case with GlaxoSmithKline’s Liquid 
Dispensing Technology© since DoD can produce multiple drops per second and can be 
scaled up further by using multiple nozzles [23].  
 
The high placement accuracy of DoD also enables the production of multi-layered dosage 
forms which is a promising application since increasing number of treatment regimens 
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involve a cocktail of different drugs (e.g., HIV-AIDS, a number of cardiovascular 
conditions and most cancer treatments). The manufacturing of multiple drugs of the 
cocktail into a single tablet or capsule is an accepted strategy for mitigating one of the 
key related problems in medical practice: assurance of patient compliance.  
 
Although different material systems with a wide range of properties can be deposited 
using DoD technology [24], until recently a limited range of materials have been used in 
the pharmaceutical drug printing applications, namely, solvent or nano-suspension based 
formulations [25], [26]. Using the developed dropwise additive manufacturing process 
for pharmaceuticals (DAMPP), different drug formulations including solvent based 
systems, i.e. solvent-polymer-API solutions, as well as melt based systems, i.e. polymer-
API melts, can be printed. Recently, Hirshfield et al. (2014) and Icten et al. (2015), 
reported proof of concept of dropwise additive manufacturing process for solvent-based 
applications and for melt-based applications, respectively. Melt-based printing 
applications eliminate the solvent evaporation step after drop deposition and thus allow 
on demand production of individual dosage forms with good control of drug solid state 
and morphology. 
 
In this chapter, the DAMPP process for melt-based dosage forms is discussed. First a 
detailed process description is presented, which is followed by the scientific and 
engineering principles of the manufacturing steps including formulation selection, control 
of operating temperature, drop formation, drop monitoring and deposition, substrate 
selection and control of substrate conditions. Then the application of DAMPP for melt-
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based pharmaceutical dosage forms is demonstrated with flexible use of different 
formulations, good reproducibility and dissolution profiles. 
 
2.2 Dropwise Additive Manufacturing Process Description 
The proto-type DAMPP process for solid oral drug products is shown in Figure 2.1. The 
process utilizes the DoD printing technology for predictable and highly controllable 
deposition of API onto an edible substrate, such as a polymeric film or placebo tablet, 
using a semi-continuous operation suitable for low volume production of personalized 
dosage forms.  
 
The DAMPP system consists of a material reservoir, precision positive displacement 
pump, xy-staging, a hot air based heating system, online imaging and sensing, and 
temperature, pump and stage controllers. The material reservoir, pump, nozzle, camera, 
substrate and staging are labelled in Figure 2.2 with numbers 1 through 6, respectively. 
The first step of the process is formulation preparation where the API is dissolved in a 
solvent- or melt-based formulation. For the melt-based formulation, a low melting point 
polymer (or alternatively a lipid or surfactant) such as polyethylene glycol, in which the 
drug dissolves once the polymer becomes molten, is used. The prepared formulation is 
placed in the reservoir, and heated until the polymer melts and the drug dissolves in the 
molten polymer. Next, the fluid formulation is pumped through an IVEK Digispense 10 
single-channel positive displacement pump with a custom controller (IVEK Corporation, 
North Springfield, Vermont), which allows for the adjustment of the drop size by 
changing the pump parameters.  
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Figure 2.1 Dropwise additive manufacturing process for pharmaceuticals (DAMPP) 
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Figure 2.2 Dropwise additive manufacturing system (1: material reservoir, 2: precision 
P/D pump, 3: nozzle, 4: camera, 5: substrate, 6: xy-stage and the dotted box: online 
imaging system) 
 
In order to maintain constant rheological properties of the printed formulation, 
temperature control is established on the whole process using hot air based heating 
system, a custom heater controller (IVEK Corporation, North Springfield, Vermont), and 
heating elements with PID controller units (Omega Engineering Inc., Stamford, 
Connecticut). After passing through the pump, the drops are ejected through a nozzle, 
15 
 
 
which can be of various internal diameter sizes as required by the specific formulation. 
An image of each drop is taken after it is ejected from the nozzle, while still on air, using 
a Manta camera with Banner motion sensors (Allied Vision Technologies, Exton, 
Pennsylvania). The size of each drop is monitored using real-time image analysis. 
 
The drops deposit onto the substrate placed on the Newport ESP301 series xy staging 
controlled by the corresponding controller/driver unit (Newport Corporation, Irvin, 
California). The xy-staging and synchronization logic allows precise drop positioning on 
the substrate while printing. The temperature of the deposited drops is controlled 
indirectly by controlling the temperature of the substrate using a Peltier device with TC-
48-20 PID controller (TE Technology, Traverse City, Michigan), which is placed on the 
xy-stage. This allows control of the rate of solidification of melts and thus control of 
nucleation and crystallization phenomena. Since the crystallization temperature profile 
has a strong effect on product solid state characteristics, influencing the dissolution 
properties and hence the bioavailability of the drug, precise control of the drop 
solidification process occurring on the substrate can be very important [27], [28]. The 
effect of controlled process parameters on the solid state and dissolution profiles of the 
dosage forms is further discussed in Chapter 5 [29]. 
 
The automation system of the process is developed using National Instruments’ 
LabVIEW 2012. The synchronization logic allows execution of the pump, staging and 
temperature controllers and imaging system simultaneously. With this system, process 
data including the volume of each drop, the location on the substrate and temperature 
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values at various process units are recorded in a data management application, which 
serves as documentation for each dosage that is produced using the DAMPP [30]. The 
resulting validated documentation is an essential record of drug product quality. The 
details of the automation and data management systems for DAMPP are presented in 
Chapters 3 and 4.  
 
Next, the details of the manufacturing steps for melt-based dosage forms are presented 
along with the scientific and engineering principles that are relevant to DAMPP. A 
detailed process schematic of DAMPP is shown in Figure 2.3. 
 
 
Figure 2.3 Process schematic of DAMPP 
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2.2.1 Formulation Selection 
Using this process, different drug formulations including solvent-polymer-API systems 
and low melting point carrier-API systems, i.e. melts, can be used. The solvent-based 
formulation consists of an organic solvent, API and a polymer. The details for solvent-
based formulations were studied by Hirshfield et al. (2014) [18]. The melt formulations 
consist of a low melting point carrier and an API, which are mixed and heated above the 
melting temperature of the mixture in order to produce hot-melts. Different carrier 
systems including low molecular weight polymers: PEG and Pluronic, surfactants: 
Gelucire and lipids: Compritol are studied. Depending on the desired final solid state 
form of the API, different carriers can be used in the formulation of solid dispersions. 
The key characteristics affecting the solid state form are the nucleation and crystallization 
growth rates of the API during melt cooling. Following Baird et al.[31], 2010, the 
crystallization tendency of organic molecules from undercooled melts can be grouped 
into three main classes, which are depicted in Figure 2.4. Class I molecules crystallize 
rapidly since they have fast nucleation and growth rates; class II molecules can either be 
crystalline or amorphous depending on the kinetics of the process relative to 
crystallization and nucleation kinetics; class III molecules stay amorphous when a nuclei 
free glass is prepared during cooling of the melts [31]. In addition to the crystallization 
cooling rates, selection of the polymer is an important factor in drug morphology, since 
the polymer may inhibit or promote crystallization of the drug [32], [33]. 
 
Polymers are added to the printing material not only to help control drug solid state 
properties, but also to establish formulation composition and material rheological 
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properties. Depending on the ratio of drug and polymer present in the formulation, the 
dosage amount can be adjusted. The material rheological properties of the formulation 
depend on the surface tension and viscosity values of different polymers used. Polymers 
or other carriers also have an effect on the bioavailability of the drug by enhancing the 
dissolution or by sustaining the release of the drug [34]–[36]. 
 
 
Figure 2.4 Critical cooling rates to avoid crystallization [31] 
 
For the DAMPP process, polymers/carriers with low melting temperature (≤ 100 °C) and 
with low melt viscosity are preferred. The former is bounded by the operating 
temperature of the DAMPP system and the latter is a requirement for the printability of 
the melts. For instance, for hot melt extrusion, polyethylene glycol (PEG) with molecular 
weights of 1500-20000 are commonly used whereas for DAMPP process, PEGs at the 
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lower end of this bound are favorable since viscosity increases with an increase in the 
molecular weight [34]. 
 
Another limitation on the operating temperature is the stability of the drug used in the 
formulation. Although the API is not melted during DAMPP operation, the formulations 
are produced by dissolving the API in the molten carrier at relatively high temperatures 
(≤ 100 °C). Therefore stability of the drug products produced via DAMPP should be 
established and shelf life determined. Shelf-life is determined by testing samples for 
product attributes susceptible to change during storage and shipping, and likely to 
influence quality, safety and efficacy of the drug [37]. These include chemical attributes, 
e.g., pH, degradation; physical attributes, e.g., appearance, particle size; in vitro drug 
release, e.g., dissolution; and biological attributes, e.g., potency. Conventional drug 
products are tested for long term or accelerated storage conditions. Using the DAMPP 
system at distributed sites is envisioned to shorten the shelf-life of drug products. 
However a protocol for establishing stability of the drug products should be developed.  
Currently, for the dosage forms produced via DAMPP, the chemical stability of the API 
is verified using HPLC experiments and in vitro drug release is analyzed through 
dissolution testing. 
 
2.2.2 Control of Operating Temperature 
In order to produce melt-based dosage forms reproducibly, the complete system must be, 
maintained at suitable temperature, which is above the melting temperature of the 
formulation, below the potential degradation temperature of the drug substance and 
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within the desired operating limits of the equipment itself (≤ 100 °C). The printability and 
reproducibility of melt-based formulations depend on material properties of the fluid 
processed, especially viscosity and surface tension, which are generally highly depend on 
temperature. Therefore temperature control on each process component, including 
reservoir, pump, tubing and nozzle, is implemented, as shown in Figure 2.3. The 
temperature of the fluid maintained in the reservoir and passing through the pump are 
controlled via the heating tape and the custom heater controller built in the pump, 
respectively. A concentric tube heat exchanger is designed to control the temperature of 
the tubing and the nozzle, where air is used as a heating medium. Air is heated by the 
custom air heater, which is connected to a proportional-integral-derivative (PID) 
temperature controller. The formulation material flows on the tube side, that is, inside the 
inner tube in the direction shown with the yellow arrow in Figure 2.2. The hot air flows 
on the shell side, that is, around the tubing and the nozzle in the countercurrent direction 
shown with the blue arrow in Figure 2.2. This structure prevents the melts from 
solidification inside the tubing and on the nozzle, and maintains the temperature at the 
desired set point.  
 
2.2.3 Drop Formation 
In the DAMPP system, the melt-based formulation contained in the reservoir is pumped 
through a DoD positive displacement pump. Drop on demand technology allows 
generation of individual drops by means of a pressure pulse upstream of the printing 
nozzle [24], [38]. Until the pressure pulse reaches a threshold value, the liquid will be 
held in place by the surface tension at the nozzle. Once the threshold value is exceeded a 
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drop is ejected [24]. By adjusting the pressure pulse used to form the drops, the drop size 
can be controlled within a defined range [24]. Different DoD printing methods, including 
thermal, piezoelectric or positive displacement pump can be used to generate the pressure 
pulse required for drop formation. In the DAMPP, the precision pump is connected to a 
custom controller that allows for variations in printing parameters such as the RPM, i.e. 
the speed of the piston rotation within the cylinder, and volume strokes, i.e. how many 
times the piston rotates within the cylinder in the pump per trigger. Besides the RPM and 
volume stroke, the displacement on the pump can also be used to adjust the size of drops 
generated.  
 
Drop formation using DOD technology has the characteristic stages as seen in Figure 2.5. 
The first four images of Figure 2.5 exhibit ejection and stretching of the fluid. Once the 
fluid in the nozzle is pushed out of the nozzle, the meniscus extends outward and a liquid 
column is formed. After this step, the flow rate of the fluid decreases. Necking and pinch-
off steps of the fluid are shown in images 5 to 9. The fluid at the nozzle exit necks and 
the radius of liquid thread continues to get thinner. Due to the high pressure in the tail, 
the surface contracts in order to decrease the surface energy, and the tail of the drop starts 
to recoil towards the head of the drop. The recoil step is displayed in images 10 to 12. 
The fluid thread continues to shrink and a second neck forms, through images 13 to 16. It 
breaks up into a primary and a satellite drop. In different conditions, the satellite drop can 
break up into more than one drop. In images 17 to 20, the satellite and primary drops 
merge to form a larger drop. Then the excessive surface energy is transformed into 
oscillatory kinetic energy and an equilibrium stage is reached [39]. 
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Figure 2.5 Piezoelectric DoD drop formation, modified from [39]. 
 
Drop dynamics is also known to be strongly influenced by surface tension and viscosity 
and can be characterized by dimensionless quantities, such as the Reynolds (Re), Weber 
(We), Ohnesorge (Oh) numbers, which are shown in Equations 2.1 to 2.3 [24], [38].  
 
Re v dUP 
 Eq. 2.1 
 
2v dWe UV 
 Eq. 2.2 
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U V
   Eq. 2.3 
 
where  U = density [kg/m3] 
V = surface tension [N/m] 
Q = velocity [m/s] 
P = dynamic viscosity [kg/s-m] 
d = characteristic length (nozzle diameter) [m] 
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The Ohnesorge number relates the viscous force relative to the surface tension force. 
Fromm has introduced a parameter to represent printability, which is the reciprocal of the 
Oh number as shown in Equation 2.4 [40]. He suggests that 𝑍 > 2  for stable drop 
formation. Another proposed range for stable drop formation is 10 > 𝑍 > 1 . At low 
values of Z, viscous dissipation prevents drop ejecting and at high values of Z, the 
primary droplet is followed by multiple satellite droplets [41]. Satellite drops are 
undesirable because they are detrimental to precision of drop deposition [39].  
 
1Z Oh  Eq. 2.4 
 
The Weber number relates the fluid’s inertia to its surface tension. There is a minimum 
Weber number before which drop breakup does not occur because a drop must have 
sufficient energy to overcome the fluid/air surface tension at the nozzle exit [24]. After 
the drop is deposited, it should leave a single isolated spread drop. The mechanisms that 
lead to splashing are still subject to research but there is an experimental threshold 
presented in Equation 2.5, where 𝑓(𝑅) is a function of surface roughness [42]. 
 
1 1
2 4Re ( )We f R!  Eq. 2.5 
 
Operating limits on the dimensionless numbers for stable drop formation have been 
determined for Newtonian fluids [24]. Figure 2.6, is established with the use of equations 
2.1 through 2.5.  
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Figure 2.6 Printable fluid properties for Newtonian fluids [24] 
 
However additional research is required for establishing such operating regimes for 
viscoelastic fluids [38], such as solutions or melts of polymer and API and such work is 
ongoing in our research team. Preliminary studies to determine the operating region for 
solvents is presented in Chapter 4. The operation region has to be chosen carefully to 
ensure the integrity of the drop until it deposits to the substrate. After ejection, a drop 
may separate into a primary and one or more secondary drops, which are called satellite 
drops [41]. Satellite drops are undesirable because they are detrimental to precision of 
drop deposition [39]. If the primary and the satellite drops do not combine to a single 
drop after ejection, they might land on a different area on the substrate and affect the final 
API loading of the form. 
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After passing through the pump, the drug material ejects through a nozzle onto the 
substrate placed on the xy staging. The tubing connected to the inlet and outlet of the 
pump is Teflon tubing with 1/8” O.D. and 1/16” I.D. with corresponding Teflon ferrules 
and fittings. In the DAMPP system, nozzles with different diameter sizes can be used: 
typical sizes used in our work are listed in Table 2.1. In order to adjust the drop size, 
nozzle diameters can be changed along with the printing parameters, such as RPM, 
volume strokes and pump displacement.  
 
Table 2.1 Nozzle sizes 
Nozzle # 1 2 3 4 5 6 
Standard Wire 
Gauge Size 
13 
AWG 
14 
AWG 
15 
AWG 
17 
AWG 
19 
AWG 
20 
AWG 
Inner Diameter 1.83 mm 1.63 mm 1.45 mm 1.15 mm 0.91 mm 0.81mm 
 
2.2.4 Drop Monitoring and Deposition 
For pharmaceutical applications, it is very important for the dosage to have the proper 
API loading. Therefore, the process conditions must be chosen carefully so that the 
potential for satellite drop formation is minimized. In order to ensure consistent drop 
formation without satellite drops, the drop formation is monitored using a moderate speed 
Manta camera based imaging system. With the help of motion sensors, an image of each 
drop is taken after it is ejected from the nozzle and before it is deposited on the substrate. 
If satellite drops are detected, printing settings can be adjusted online to obtain stable 
drop formation. The captured drop image is converted to drop volume using pixel counts 
within a shape model that can accommodate arbitrary rotational symmetry [43]. To 
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demonstrate the reproducibility of the drops, a melt of PEG 3350 is printed using the 15 
AWG nozzle, 2.5 displacement, 1200 RPM and volume strokes of 1. Drop images 
captured with the imaging system are shown in Figure 2.7. The average volume of the 
drops printed with this formulation and printing settings is 13.70 µL with a relative 
standard deviation of 1.59 %. The details of the automation system including the imaging 
system and the volume calculation are presented in Chapter 3.  
 
Drop positioning is accomplished by locating the printer nozzle above the desired 
location on the substrate before ejection. The xy-staging and synchronization logic allows 
creating precise drop positioning on the substrate while printing and enables layering of 
different drugs. The drops are deposited in a grid structure using the DAMPP system, as 
shown in Figures 2.2 and 2.3. The behavior of a drop on impacting a solid surface is 
controlled by a number of physical processes including the drop velocity, size, drop 
material properties, distance from the surface and surface properties [24], [44]. Upon 
impinging the drop can splash, spread or even rebound [44]. In order to achieve a single 
isolated drop without splashing or spreading, the physical process parameters must be 
suitably selected. Since solidification of drops occurs post-deposition, melt-based 
formulations must retain some stability in the liquid state prior to solidification. 
 
 
Figure 2.7 Images of PEG 3350 drops printed with DAMPP 
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Figure 2.8 Melt-based formulations during deposition on a. polymeric films b. placebo 
tablets 
 
2.2.5 Substrate Selection 
Using this process, the formulations can be printed on a variety of substrates including 
polymeric films and placebo tablets or into capsules. Printing melt-based formulations on 
edible polymeric films and on placebo inert tablets are shown in Figure 2.8. Surface 
properties of the substrate onto which the drops are deposited have an effect on drop 
deposition characteristics as well as on the solid state of the drug. The use of polymeric 
films or inert tablets of different porosities can have an effect on the crystallization and 
dissolutions profiles of the formulations. It has been shown that by printing on films 
containing HPMC or chitosan, the microstructure, crystallinity and even the dissolution 
of drug deposits can be controlled [45]. The surface chemistry of chitosan films, such as 
its capability of forming H-bonds with the drug, also effects the crystallization of drugs 
[46]. The surface properties of the substrate, such as roughness, also can have an effect 
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on product morphology [26], [47]. Therefore the substrate should be selected by 
considering the desired end product.  
 
2.2.6 Control of Substrate Conditions 
The temperature of the deposited drops are controlled via the Peltier device with PID 
controller placed on the xy staging underneath the substrate. This allows control of the 
rate of solidification of melts and thus control of nucleation and crystallization 
phenomena. Since crystallization temperature will have an effect on product solid state 
characteristics, influencing the dissolution properties and hence the bioavailability of the 
drug, precise control of the drop solidification process once the drop is deposited on the 
substrate is essential [48]. This is achieved indirectly by manipulating the substrate 
temperature profile using controlled temperature gradients [28]. Using the substrate 
temperature control strategy explained in Chapter 5, the crystallization behavior can be 
tailored and consistent drug properties achieved [28].  
 
2.2.7 Confirmation of Solid-State Form 
After the dosage forms solidify, the solid state form of the drug substance should be 
verified by an online or offline technique such as X-ray diffraction, microscopy or a 
spectroscopic technique. The noninvasive nature of spectroscopic techniques, including 
Raman and Near Infrared (NIR) spectroscopies, allows continuous real-time 
measurements of critical product properties without sample preparations [49]. For 
instance, they can also be used to distinguish different polymorphic forms [50]. The best 
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technique to verify the crystallinity or drug polymorphic form in the dosage forms can be 
selected based on the drug formulation. 
 
2.2.8 Postprocessing 
After the dosage forms are produced, a number of different post-processing steps can be 
applied, including coating of dosage forms to insure adhesion of deposit on the substrate, 
to shield the API from moisture, to alter the dissolution profile of the drug, or for taste-
masking. For multilayered drug production, another layer of the same drug or another 
drug could be printed to adjust the dosing or to produce a drug cocktail for a specific 
treatment. 
 
2.3 Materials and Methods for the Analysis of Melt Based Drug Products 
DAMPP is used to produce solid oral dosage forms from hot-melts of an active 
pharmaceutical ingredient and a polymer. The dosage forms are analyzed to show the 
reproducibility of dosing and the dissolution behavior of different formulations. In this 
section the materials used in the formulation of the drug products and the methods used 
to analyze those products are demonstrated. 
 
2.3.1 Materials and Formulation Preparation 
In this study, naproxen is chosen as the model API to form melt formulations either with 
the polymer, polyethylene glycol with a molecular weight of 3350 or with the block 
copolymer Pluronic F38 with a molecular weight of 4700. Naproxen (NAP) was 
purchased from Attix Pharmaceuticals (Montreal, QC, Canada). PEG 3350 and Pluronic 
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F38 were provided by The Dow Chemical Co. (Midland, Michigan) and BASF (Florham 
Park, New Jersey), respectively. Naproxen and the polymer (PEG 3350 or Pluronic F38) 
were mixed in (15:85) weight ratio. The mixture is comelted at 65 °C until completely 
melted. The melt formulation is printed on polymeric films prepared with hydroxypropyl 
methylcellulose (HPMC) (E50) and PEG 400. HPMC (E50) is purchased from Sigma 
Aldrich Corporation (St. Louis, Missouri). PEG 400 likewise was provided by The Dow 
Chemical Co. (Midland, Michigan). 
 
2.3.1.1 Film Preparation 
In order to make a 5% (w/v) polymer solution, 0.6 gr HPMC powder (E50) and 0.4 gr 
PEG 400 were dissolved in 20 ml water at 90 °C. The 5% (w/v) HPMC-PEG 400 
solution was stirred at room temperature overnight to ensure that the polymeric chains 
were homogeneously dispersed in the solution and cast onto a Petri glass. After drying 
was completed, the film was peeled off. 
 
2.3.2 Methodology 
After deposition of the drops onto the film, the resulting dosage forms were analyzed to 
determine whether the different formulations would affect the dissolution behavior of the 
API. The dosage forms were created and analyzed at the same time and thus varying 
ambient conditions, such as relative humidity, were not impactful on the results. 
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2.3.2.1 Hot Stage Microscopy Experiments 
Formulation consisting of naproxen and polymer were prepared as described in Section 
2.3.1. After the solid dispersions solidified, they were ground using a mortar and pestle. 
The resultant powder was evaluated using a Nikon Eclipse E600 polarized light 
microscope (Nikon Inc., Melville, New York) equipped with a Linkam THMS 600 hot-
stage (Linkam Scientific Instruments Ltd., Surrey, UK). The samples were heated at 
1 °C/min until completely melted. The temperature where the last crystal melted was 
recorded and was used to construct the phase diagram. 
 
2.3.2.2 High Performance Liquid Chromatography Experiments 
Quantification of the drug in the dosage forms was done using an Agilent 1260 infinity 
high performance liquid chromatography (HPLC) system using an Agilent plus C18 5μm, 
2.1x150 mm column (Agilent Technologies, Santa Clara, California). The mobile phase 
consisted of acetonitrile (ACN) as the organic phase and pH 2.5 phosphate buffer as the 
aqueous phase. Isocratic elution was performed on the samples at a flow rate of 0.5 
mL/min with the mobile phase consisting of 60% aqueous phase and 40% ACN. 
Naproxen was detected at a wavelength of 210 nm using an ultraviolet detector. The 
retention time of naproxen was 4.5 min using the method listed above. A calibration 
curve was plotted from 1μg/mL to 100 μg/mL with a R2 value of 0.9999. For analysis of 
the dosage forms, individual drops of naproxen-PEG 3350 and naproxen-Pluronic F38 
were dissolved in ACN and diluted appropriately to obtain the concentration in the range 
of the calibration curve.  
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2.3.2.3 Reproducibility of Dosage Amounts 
Different drop sizes are used to produce the dosage forms with target dosage of 15 mg of 
API. The different drop sizes are obtained by changing the pump and printing operating 
parameters such as nozzle diameter, displacement, volume strokes and rate. The number 
of drops needed to reach the target amount varied for each printing setting and was 
determined experimentally before producing the dosage forms. To analyze 
reproducibility, HPMC-PEG 400 film measuring 2 cm by 2 cm was weighed on an 
Omega AL-201s balance. Next, a specific number of drops were deposited on the film to 
reach the target dosage amount. The films were then subjected to room temperature until 
the deposits solidify. After solidification of the drops, the films were weighed again to 
determine the total mass of the deposits on the film. The amount of drug was determined 
by multiplying this mass of solids by the composition of drug in the solution (15%). 
These results were then used to analyze how consistently and accurately the dosage forms 
are created. 
 
2.3.2.4 Dissolution Testing 
The dissolution test was conducted using USP-I apparatus (Agilent Varian VK 7010) at 
100 rpm.  The dissolution media consisted of the USP phosphate buffer solution of pH 
7.4, which was maintained at 37 °C. The experiments were performed in sink conditions 
to prevent the drug from saturating the dissolution media. The experiments were run for 
90 minutes, and aliquots of the dissolution medium were collected at intervals of 3 
minutes through 35 micron full flow filters (Agilent filters) by a peristaltic pump. Sample 
33 
 
 
absorbance was measured by a UV spectrophotometer (Cary 50) at 243 nm. Absorbance 
values from the spectrophotometer were used to calculate the percent release of the API 
from the films. Each experiment was performed in three replicates. 
 
2.3.2.5 X-ray Diffraction 
X-ray diffraction was performed on the dosage forms to confirm the physical nature of 
naproxen. The drops were loaded onto glass sample holders and data collection was 
performed using CuKα radiation from a Rigaku SmartLab diffractometer (The 
Woodlands, Texas) at 40kV and 20mV. Measurements were performed in the range of 5-
35° 2θ with a scan rate of 4° 2 θ/min and a step size of 0.04° using Bragg-Bretano mode. 
Si peak was used as an external reference standard. Diffractograms of the crystalline drug, 
PEG 3350, Pluronic F38 and physical mixture of the drug with the polymers were 
collected as reference. 
 
2.4 Analysis of Melt-Based Dosage Forms 
In order to demonstrate the performance of DAMPP system, dosage forms of melts are 
produced using different formulations. The first formulation consists of 15% naproxen 
and 85% polyethylene glycol 3350 (PEG 3350) by weight. This formulation is selected 
based on the studies done by Zhu et al., which shows that naproxen and PEG 3350 form a 
eutectic system with a eutectic composition of around 15% naproxen [51]. The dosage 
forms are shown in Figure 2.9. 
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Figure 2.9 Dosage forms containing Naproxen/PEG 3350 formulation deposited on a. 
inert tablets b. HPMC film 
 
The second formulation consists of 15% naproxen and 85% Pluronic F38 by weight. The 
phase diagram for naproxen/Pluronic F38 solid dispersions is constructed using optical 
microscopy to determine the melting point depression of mixtures of various 
compositions and is shown in Figure 2.10. The liquidus temperature refers to the 
temperature at which the mixture is entirely liquid. The eutectic composition of Pluronic 
F38 and naproxen is determined between 10% and 15% of naproxen by weight. 
Therefore both formulations are prepared with 15% naproxen and 85% polymer. 
 
The formulations were comelted at 65 °C and the temperature of the system was 
controlled at 70 °C throughout the process. The molten formulations were subject to the 
operating temperature of 70 °C during the maximum residence time of 5.4 minutes which 
is determined for the smallest drop size of 9 µL. For larger drop sizes the residence time 
is shorter as the number of drops deposited per time is fixed. In order to check the 
chemical stability of naproxen under production, we performed HPLC experiments on the 
dosage forms, which were intentionally subjected to 70 °C for 15 min during production. 
The HPLC experiments showed that naproxen found in the dosage forms is stable. The 
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amount recovered is the same of the amount present in the dosage forms and no 
degradation peaks were observed. 
 
 
Figure 2.10 Phase Diagram of Naproxen / Pluronic F38 
 
2.4.1 Reproducibility of Dosage Forms 
To demonstrate different drop sizes, two intermediate sizes of nozzles (i.e. with internal 
diameters of 15AWG and 17AWG) are used. The pump settings are determined to 
achieve consistent drop formation for both formulations using these nozzle sizes. Using 
the DAMPP system, dosage forms are produced by printing different sizes of drops on 
HPMC-PEG films as the substrate. The reproducibility of the dosage forms so produced 
is shown in Table 2.2. The relative standard deviation (RSD) is less than 1% for most 
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cases and up to 2% for others. These RSD values are well within the 5% RSD limit 
required by the FDA. 
 
Table 2.2 Reproducibility analysis of dosage forms 
Formulation Number of drops printed 
Average dosage 
amount (mg) RSD (%) 
15% Naproxen 
85% PEG 3350 
10 14.32 0.56% 
9 15.69 0.18% 
7 16.13 0.05% 
6 15.53 1.30% 
15% Naproxen 
85% Pluronic F38 
10 15.76 0.69% 
9 16.11 2.05% 
7 15.12 0.08% 
6 13.77 0.17% 
 
2.4.2 Dissolution Testing 
Dissolution testing was performed on the dosage forms produced with different sizes of 
drops and different formulations. In Figure 2.11, the dissolution profiles of the dosage 
forms with the first formulation, i.e. containing 15% naproxen and 85% PEG 3350 are 
shown. Dissolution of 98% was achieved in one hour and 85% within 20 minutes. In 
Figure 2.12, the dissolution profiles of the dosage forms with the second formulation, i.e. 
containing 15% naproxen and 85% Pluronic F38 are shown. Dissolution of 99% 
dissolution was achieved in one hour and 85% in 33 minutes.  
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Figure 2.11 Dissolution profiles of dosage forms created with different number of drops 
of the formulation containing PEG 3350. 
 
For both formulations, there are slight differences in the dissolution profiles of the dosage 
forms printed using different drop sizes. This is due to the effect of the cooling 
temperature gradient within the drops as they are solidifying which can lead to 
morphology changes. By applying temperature control on the substrate, one can 
overcome the effect of temperature gradients due to different drop sizes and tailor the 
dissolution behavior [28]. The effect of temperature is discussed in Chapter 5. 
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Figure 2.12 Dissolution profiles of dosage forms created with different number of drops 
of the formulation containing Pluronic F38. 
 
2.4.3 Effect of Formulation on Dissolution 
The effect of formulation on the dissolution profile is shown in Figures 2.13 and 2.14. 
Here, the dosage forms created with 6 drops of large size and 10 drops of small size are 
compared for the PEG 3350 and Pluronic F38 containing formulations. Dosage forms 
with PEG 3350 formulation have a faster dissolution than the dosage forms containing 
Pluronics F38. This is a result of the structural differences between the two polymers.  
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Figure 2.13 Effect of formulation (PEG 3350 vs Pluronic F38) on the dissolution of 
dosage forms consisting of large drops. 
 
PEG is a polymer of ethylene oxide (EO) and is hydrophilic with a good solubility in 
water [34]. It is known to enhance dissolution of many drugs that have poor solubility 
[34], [36]. Pluronic is a triblock copolymer which consists of repeating chains of EO and 
propylene oxide (PO) in the structure of EOx-POy-EOx, where x and y are the average 
number of EO and PO units respectively [52], [53]. Pluronic F38 consists of 80% EO 
with a structure of EO43-PO16-EO43. Although Pluronic type polymers are amphiphilic 
with hydrophilic EO and hydrophobic PO units, those with 80% PEO blocks are 
considered as very hydrophilic block copolymers with high solubility [53]. However the 
presence of PPO blocks in the Pluronic F38 containing formulation results in a slower 
release of the drug compared to PEG 3350 containing formulation. Another difference in 
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the dissolution profiles are the larger error bars observed for the Pluronic F38 containing 
formulation compared to the PEG 3350 containing formulation. This can also be related 
to the differences in the structures of the two polymers, where amphiphilic Pluronic units 
could potentially cause varying release profiles. 
 
 
Figure 2.14 Effect of formulation (PEG 3350 vs Pluronic F38) on the dissolution of 
dosage forms consisting of small drops. 
 
For the model drug used, the first formulation which leads to faster dissolution is 
favorable but the use of the Pluronic type polymers might be favorable for some other 
drugs. Pluronic not only increases oral solubility of poorly soluble drugs by its 
hydrophilic EO side but it can also enhance the oral absorption of selected drugs with its 
ability to form unimers or micelles [52]. Pluronic type polymers with large PPO blocks 
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can self-assemble into micelles in aqueous environments and the PO core can serve as a 
‘cargo’ for the incorporation of various hydrophobic compounds that exhibit poor 
solubility, undesired pharmacokinetics and low stability in physiological environment 
[52], [54]. Unimers of Pluronic block copolymers increase membrane transport and 
transcellular permeability in intestinal epithelium cells thus inhibit drug efflux systems in 
intestinal epithelial cells [52], [55], [56]. Overall, Pluronic block copolymers may be 
useful in designing formulations to increase bioavailability of select drugs.  
 
 
Figure 2.15 XRD spectra of crystalline naproxen, PEG 3350, Pluronic F38, and physical 
mixtures of both formulations and resulting dosage forms. 
 
With the model formulations used in this study, the amorphous form of naproxen is not 
observed in the presence of PEO, which promotes crystallization of naproxen [51]. X-ray 
diffraction studies showed that the naproxen present in the dosage forms is crystalline 
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and present in the same polymorphic form as the material used in the formulations both 
in the presence of PEG 3350 and Pluronic F38 which is shown in Figure 2.15. However 
amorphous forms can be potentially produced with alternative choices of operating 
conditions and polymers, which inhibit crystallization. Amorphous drug forms can offer 
improved dissolution performance thus higher bioavailability. However, since the 
amorphous API is a metastable state, precise temperature control and design of 
crystallization temperature profile are required in order to achieve the desired solid state 
form.  
 
2.5 Conclusions 
A dropwise additive manufacturing system of pharmaceutical products (DAMPP) for 
melt-based dosage forms is developed which takes various scientific and engineering 
principles into account. The temperature controlled process enables the production of 
melt-based pharmaceuticals reproducibly and consistently. Using the DAMPP system, 
different polymer containing formulations are used to enhance the bioavailability of the 
model drug: naproxen.  Alternative formulations based on other active ingredients and on 
other carriers such as other low-melting point polymers, lipids or surfactants can be used, 
as well. 
 
The imaging system enables monitoring the drop sizes and therefore the dosage amounts. 
The dosage amount can be adjusted according to patients needs by simply changing the 
drop size and/or the number of drops in each dose. For the formulations studied in this 
chapter, differences are observed in the dissolution profiles of the dosage forms printed 
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using different drop sizes. This is because of the cooling temperature gradient observed 
within the drops during solidification which can lead to morphology changes. By 
applying temperature control on the substrate, one can overcome the effect of 
temperature gradients due to different drop sizes and tailor the dissolution behavior. 
Achieving the same dissolution behavior for each dose regardless of the drop size enables 
the application of the DoD system for the production of individualized dosage regimens 
for adaptive clinical trials and personalized treatments. The effect of temperature control 
is discussed in the subsequent chapters. The prototype system offers great promise as a 
tool for advancing personalized therapies by allowing the precise production of 
convenient solid oral dosages tailored to the patient on site at hospitals, clinics and even 
pharmacies. 
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 REAL TIME PROCESS MANAGEMENT STRATEGY FOR CHAPTER 3.
DROPWISE ADDITIVE MANUFACTURING OF PHARMACEUTICALS† 
3.1 Introduction 
To address the challenges associated with producing high quality pharmaceutical 
products, the DAMPP process allows the application of process control, on-line 
monitoring and fault diagnosis systems. Since the process is small-scale, consists of 
simple unit operations, and involves fluid processing, as opposed to the solids processing 
used in conventional processes for pharmaceutical solid oral dosage products, the 
implementation of automation and low-level control for DoD systems is comparatively 
simpler [57], [58]. There are some complexities involved with controlling drop dynamics 
which require attention and a unique control and monitoring strategy. The formation and 
behavior of drops is affected greatly by material properties; the surface tension and 
viscosity of the fluid, in particular, are important to consider in relation to the pressure 
that is applied to the nozzle [59]. The viscosity of the drop should be low enough to 
ensure that a drop will actually eject from the nozzle but high enough that the fluid does 
not splash out of the nozzle [38].The surface tension must be high enough so the fluid 
does not leak from the nozzle at rest and to ensure the drops form uniformly [38].  It has 
                                                 
† This chapter is based on: L. Hirshfield, E. Içten, A. Giridhar, Z. K. Nagy, and G. V. 
Reklaitis, “Real-Time Process Management Strategy for Dropwise Additive 
Manufacturing of Pharmaceutical Products,” J. Pharm. Innov., vol. 10, no. 2, pp. 140–155, 
2015.  
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been said that the “only way to check the quality of a printing process is by checking the 
result, as the process itself does not give any direct feedback [60];” so in addition to 
traditional process control, there must be a careful automation strategy and sufficient on-
line monitoring to ensure a quality product. Therefore, DAMPP necessitates an advanced 
real-time process management (RTPM) strategy, encompassing automation of each unit 
operation, careful control of process parameters, monitoring of the process and product 
quality and an exceptional events management system that detects and diagnoses process 
faults that are outside of regulatory control. 
 
This chapter presents the RTPM strategy developed for the DAMPP system [30]. An 
automation program makes the unit operations run synchronously, while maintaining the 
control of equipment and recording the various monitored parameters. The printing 
material and process temperatures are carefully controlled to maintain consistent material 
properties and thus predictable drop dynamics, while the process temperature is 
manipulated to control the product's final dosage form morphology. Each drop is 
monitored with a vision system, allowing for the calculation of drop size, storage of the 
process parameters, drop images and drop characteristics for each deposited drop. Image 
capture of each drop also allows for the management of exceptional events. With careful 
selection of process parameters and printing materials and a successful RTPM strategy, 
DAMPP allows for precise and accurate control of the dosage amount, composition, 
phase, morphology, and release profile of the drug, all through monitoring and 
controlling critical process parameters and critical product quality attributes. Moreover, 
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since each dosage is tracked as it is formed, deviations can be identified and eliminated as 
they are produced, providing real time release functionality. 
 
3.2 Development of a Real Time Process Management Strategy 
For pharmaceutical processes, the performance of a drug product is defined in terms of its 
critical quality attributes (CQA), which are its essential physical, chemical and biological 
characteristics [61]. For the dropwise additive manufacturing system, the desired critical 
quality attributes (CQA) of the dosage forms that should be kept within the appropriate 
limits are the dosage amount and drug morphology. The CQAs were determined by 
identifying the key characteristics of a quality dosage form: the API should be deposited 
in the proper amount for the patient (dosage amount) and in the desired form: amorphous 
or crystalline (drug morphology). The critical process parameters (CPP) that have a direct 
impact on the CQA’s, are the drop size, product and process temperatures, as shown in 
Table 3.1. 
 
Table 3.1 Critical quality attributes and critical process parameters  
Critical Quality Attributes (CQA) Critical Process Parameters (CPP) 
Dosage amount Drop volume 
Dosage form morphology 
Process temperature 
Product temperature 
 
By knowing the concentration of the API in the printing fluid, the dosage amount can be 
determined from the drop volume. It is important to monitor the drop via imaging, not 
only to calculate the drop volume, but to track the drop’s trajectory and detect any 
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possible faults in the drop formation system. On-line Raman or NIR measurements can 
also be used to confirm API concentration in the solid dosage. For a given formulation, 
the drug morphology can be ensured by controlling the process temperature and the 
temperature of the product after the drops have been deposited. Temperature control of 
the process maintains material properties and ensures printability of the fluid, while 
temperature control of the product affects rate of solidification of melts or evaporation of 
solvents and thus control over crystallization phenomena.  The dosage form morphology 
and drug’s solid state behavior can be monitored on-line using a spectroscopic method 
such as NIR or Raman [49]. The RTPM strategy developed for DAMPP consists of four 
main steps and is shown in Figure 3.1. 
 
 
Figure 3.1 RTPM strategy for DAMPP 
 
1. Automation consists of logic programming to drive synchronous execution of all 
unit operations, including controllers and instruments, and to ensure automatic 
completion of the entire drop deposition process.  
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2. Regulatory control is used to maintain the CPPs within a normal operating 
regime in the presence of common cause variations.  
3. An online monitoring strategy is needed to ensure that the CQAs of the product 
are within specifications. It consists of various sensors, on-line spectroscopy, and 
imaging equipment. 
4. Exceptional events management (EEM) helps to detect and mitigate infrequent 
failures that may arise during process operations due to special causes.  In the 
context of pharmaceutical dosage manufacturing, this capability insures that 
production of noncompliant dosage is minimized and any such production 
immediately isolated. 
 
The components of RTPM strategy is discussed in the following sections. The 
Exceptional Events Management is explained in Hirshfield et al.(2015) and is the subject 
of Dr. Hirshfield’s dissertation [30], [62]. 
 
3.3 Automation 
A LabVIEW program has been developed for synchronous execution of the pump, 
staging and camera and also incorporates the control and monitoring methods discussed 
previously. The user interface of the automation program is shown in Figure 3.2. This 
section describes the automation program in detail, including the input variables the user 
must define, the steps that the program executes, and the outputs of the program. The 
performance of the automation program is also presented; specifically, what 
manufacturing throughput can be achieved with the use of the program.  
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Figure 3.2 The user interface of the LabVIEW- based automation program 
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The automation system is integrated with the knowledge management system (KMS) 
designed for DAMPP. In the knowledge management system, all the input data are saved 
to a file, which needs to be uploaded to the LabVIEW automation program. After the 
process run, automation program generates an output file containing all the output data. 
The integration of the automation program with the knowledge management program is 
discussed in Chapter 4. 
 
3.3.1 Program Inputs 
First, the user must define the inputs through the KMS system. 
 
x Printing Settings 
o Pump displacement – The setting of the pump displacement. It can have a 
value between 1 and 4. 
o Nozzle diameter – The diameter of the nozzle used in millimeters. 
o Pump rate – The setting of pump rate. Has a value between 0-999 
corresponding to % RPM. 
o Volume stroke – This setting corresponds to how many times the piston 
rotates within the cylinder in the pump per trigger. Preferably, it has a 
value of 1 or 2. 
x Deposition Settings 
o Sheet ID – The number of sheet, which is used as the substrate. 
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o Deposition pattern – The number of selected deposition pattern. It can be a 
grid pattern with boustrophedonic movement (#1) or row by row 
deposition (#2). 
o Home position (x) and (y) – The starting position of the drop grid pattern. 
This is variable depending on the substrate’s position on the staging and 
where the grid pattern will be deposited over the substrate. 
o Number of columns (x) – The program executes a grid pattern of drops. 
This parameter refers to the number of columns, or number of drops in the 
x direction. 
o Number of rows (y) – Similarly, this parameter is the number of rows, or 
number of drops that deposit in the y direction. 
o Distance in X and Y – The distance, in millimeters, between each drop 
space on the grid in x and y directions. The distance must be sufficient so 
that drops do not coalesce together. In case of the deposition on tablets, 
the distance should be same as the distance between tablets on the tablet 
holder. 
o Staging delay – The delay, in milliseconds, for staging to move to the 
following deposition position. The delay should be sufficient enough for 
the stating to move to the next drop position in order to avoid coalesce. 
x Temperature Settings 
o Temperature control – This switch turns the temperature control on or off. 
For solvent systems, the temperature control may be turned off and then 
the process will proceed at ambient conditions. For melt systems the 
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temperature control should be turned on so that the reservoir, tubing, and 
substrate temperatures are controlled. If the temperature control is turned 
off, a “0” is saved and if it is on, a “1” is saved. 
o Substrate control – This turns the substrate control off or on.(0/1) 
o Substrate mode – This switches the Peltier devices from being used as 
either a heating device (“0”) or a cooling device (“1”). 
o Reservoir temperature setpoint – The temperature, in °C, of the material 
within the reservoir. This is important for melt systems so the polymer 
solid will liquefy and become printable. 
o Tubing temperature setpoint – The temperature, in °C, of the tubing and 
nozzle. 
o Substrate temperature setpoint – The temperature, in °C, of the substrate 
during the drop deposition pattern.  
o Pump temperature – – The temperature, in °F, of the pump during the drop 
deposition pattern.  
 
The input file containing all the program input data is generated through the KMS system. 
The input file is shown in Figure 3.3. 
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Figure 3.3 Input file in CSV format 
 
Before starting the DAMPP program, the user must define the file paths through the 
automation program. 
 
x Input file path – This refers to the file name where the comma separated values 
(CSV) input file containing each of the program inputs is saved. Automation 
program will read the inputs from this file automatically and display on the user 
interface shown in Figure 3.2. 
x Output file path – This refers to the file name where the comma separated values 
(CSV) output file containing each of the program outputs will be saved after the 
program run finishes. 
x Image file folder – The folder where the drop images will be saved. 
 
After the user defines the file locations and starts the program, it proceeds as shown in 
Figure 3.4. 
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Figure 3.4 Automation process of DAMPP 
 
3.3.2 Program Outputs 
Various process parameters, a drop image and image analysis are saved for each drop. 
The drop data and image analysis data are written to two separate CSV files. The image 
analysis methods are discussed in a following section. At the conclusion of the drop 
deposition process, the output files are merged into one data file. This section details the 
data that is saved for each drop. 
 
x Drop data 
o Time at which the drop deposited 
o Sheet ID, showing on which substrate sheet the drop is deposited. 
o Drop number, calculated by 1+xi+j where i is the row the drop is located 
(in the y direction) and j is the column (in the x direction) 
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o The location of the drop on the stage in the x-direction (mm) 
o The location of the drop on the stage in the y-direction (mm) 
o The temperature of the reservoir (°C) at the time of deposition. If the 
temperature control is turned off, the temperature is recorded as the 
absolute zero “-273.” 
o The temperature of the tubing (°C) at the time of deposition. If the 
temperature control is turned off, the temperature is recorded as the 
absolute zero “-273”. 
o The temperature of the substrate (°C) at the time of deposition. If the 
temperature control is turned off, the temperature is recorded as the 
absolute zero “-273”. 
o The power output of the substrate heating devices (as a percentage) 
o Pump displacement – The setting of the pump displacement.  
o Nozzle diameter – The diameter of the nozzle used in millimeters. 
o Pump rate – The setting of pump rate (% RPM). 
o Volume stroke – Number of piston rotations within the cylinder in the 
pump per trigger.  
o The temperature of the pump  in (°F). 
x Image analysis data 
o Drop volume (µL) 
o X coordinate of the center of the drop in the image (pixels) 
o Y coordinate of the center of the drop in the image (pixels) 
o File path of the drop image 
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An example of the written outputs in a CSV file is shown below in Figure 3.5. 
 
 
Figure 3.5 Output file in CSV format 
 
3.3.3 System Performance 
The automation code is designed to reach an optimal production rate with the current 
equipment. The fastest possible communication with the temperature, pump and staging 
controllers is established by operating with the minimum communication times required 
by the individual controllers. 
 
In order to eliminate the first drop effect in the beginning of each row, the time spent 
between the deposition of each drop is fixed [39]. After printing a row in the positive x 
direction, the staging moves so the nozzle is positioned over the next row and the system 
continues printing in the negative x direction. This boustrophedon movement, shown in 
Figure 3.6, allows minimizing the time required for the stage movement. 
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Figure 3.6 Boustrophedon movement path 
 
The performance of DAMPP using the LabVIEW automation system is summarized in 
Table 3.2. The time required to initialize the process refers to the time spent before the 
ejection of the first drop communicating with the controllers and setting the process input 
parameters by the user. The time is longer for melt-based systems than the solvent-based 
systems due to the added communication time with the temperature controllers. The time 
spent for the deposition of one drop and recording the data is also shorter for solvent-
based systems, which do not require as much temperature control. 
 
Table 3.2 Process performance for different formulations 
Time Spent Solvent-Based Drop Deposition Melt-Based Drop Deposition 
For initialization 5.74 sec 9.55 sec 
Per drop 2.24 sec per drop 2.64 sec per drop 
 
3.4 Feedback Control 
Although regulatory control is relatively simple to implement on drop-on-demand 
systems like DAMPP, there are nonetheless challenges that arise [57], [58]. Feedback 
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control is based on applying a correction that depends on the deviation between the 
current measurement of a critical attribute and the desired or setpoint value of that 
attribute. Given the fast dynamics of drop formation, the control system is unable to 
correct for the deviations observed during the drop formation but instead can only apply 
those corrections to the next drop to be generated. However, by carefully tuning of 
process parameters to achieve robust operation, it is possible to limit feedback control 
action to maintain critical attributes within acceptable ranges and reduce the possibility of 
off-specification product. One aspect of the process that is readily controllable is the 
environment of the printing process; specifically, the temperature at each point in the 
process.  
 
In DAMPP, we are controlling the temperature at four locations. We can control the 
temperature of the process at three points: (1) in the printing material reservoir, (2) in the 
pump and (3) throughout the tubing and nozzle in order to control the temperature of the 
printing material during deposition. We control the temperature of the product at point (4) 
underneath the substrate to control the product after it has been deposited. Figure 3.7 
shows the points of temperature control in the system. Controlling the temperature at 
points (1)-(3) allows for control of the process temperature while controlling the 
temperature at point (4) allows for direct control of the resulting dosage form product, by 
controlling the temperature of the substrate during and after the drops have been 
deposited. 
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Figure 3.7 Points of temperature control in DAMPP process 
 
3.4.1 Process Temperature Control 
While depositing solvent-based systems, temperature control is not necessary but it can 
be beneficial to minimize temperature effects on fluid properties. It is best to maintain the 
process at ambient or lower temperatures in order to control solvent evaporation. 
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However, when depositing melts, controlling the temperature of the process is essential 
for three reasons. First, the polymer must be melted and liquefied so it is printable. 
Second, since material properties (specifically, surface tension and viscosity) affect the 
drop dynamics so greatly, it is important to ensure that the predicted material properties 
are maintained throughout the process [60]. Third, temperature of the material needs to 
be regulated throughout the process to maintain the concentration (mass per volume) of 
drug within the fluid, as the calculation of the amount of API per drop volume uses this 
parameter. 
 
The process temperature is currently controlled at three points: the reservoir, the pump 
and the tubing. 
 
3.4.1.1 Reservoir Temperature Control: 
It is important to have a heated fluid reservoir when depositing melt systems in order to 
melt and hold the polymer system as a liquid. The temperature must be controlled 
carefully to maintain constant fluid properties and thus have predictable drop dynamics. 
The temperature of the reservoir at point (1) is controlled using heating tape and a PID 
controller. The LabVIEW program allows the user to input the temperature setpoint, and 
then the program calculates and sets the high and low alarms for the controller based on a 
user-specified range of acceptable temperatures around the setpoint. The PID controller 
can be tuned automatically; this involves the controller cycling the output, measuring the 
process response, and then calculating and storing the optimal PID values. 
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3.4.1.2 Pump Temperature Control: 
It is most important to control the temperature in the pump in order to maintain the 
printing fluid’s material properties and to ensure that no polymer melt solidifies in the 
pump. The temperature of the pump at point (2) is controlled via an IVEK-assembled 
PID controller. This PID controller is also tuned automatically. The temperature setpoint 
of this controller is entered manually and is not currently adjusted from LabVIEW. 
 
3.4.1.3 Tubing and Nozzle Temperature Control:  
The temperature of the tubing and nozzle must be controlled in order to maintain material 
properties and also to prevent the material from solidifying and causing clogging within 
the tubing. The temperature of the tubing and nozzle at point (3) is controlled using a 
custom air heater and a PID controller. The control of the tubing is similar to that of the 
reservoir: the LabVIEW program allows the user to input the temperature setpoint, and 
then the program calculates and sets the alarms for the controller. This PID controller is 
also tuned automatically.  
 
3.4.2 Product Temperature Control 
As discussed previously, the printing material, drop size and substrate all have an effect 
over the dosage form morphology. Controlling the substrate conditions during and after 
deposition at point (4) is an additional way to affect the solid’s crystallization and thus 
ultimately dissolution behavior after it is deposited onto the substrate [28]. As in 
traditional crystallization processes, temperature directly influences the crystallization of 
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the API, by affecting both the nucleation rate and crystal growth rate [48]. When printing 
solvent formulations, the cooling or heating rate of the dosage form after deposition also 
affects the evaporation of the solvent. The evaporation of the solvent then affects the 
liquid composition and thus the nucleation and crystallization rates as well. Therefore, the 
crystallization behavior of the drug is dependent not only on the melting temperature and 
glass transition temperature of the API, but on the solvent formulation properties as well: 
more specifically, the concentration, temperature and solubility properties of the API in 
the solvent [48]. When printing melt formulations, it may be preferable to cool the 
substrate in order to solidify the drops more rapidly, but the morphology may need to be 
controlled by reheating the dosage form, possibly in heating/cooling cycle. Therefore, 
when depositing either solvent-based formulations or melt-based formulations, the 
temperature of the substrate must be optimized to balance the needs to decrease 
production time by cooling or heating of the substrate to affect evaporation rate or 
solidification rate and also heating the substrate to control the drug morphology. 
 
The temperature of the deposited drops are controlled via the Peltier devices with PID 
controller placed on the xy staging underneath the substrate. In order to achieve the 
desired response characteristics, the temperature controller had to be tuned. An online 
controller tuning approach has been used and the control parameters have been supported 
with Ziegler-Nichols method. 
 
The user interface of the program can be seen in Figure 3.8. Using the program, the user 
can: 
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x enable or disable the output action of the controller, 
x set the desired temperature set point, 
x read the actual temperature, 
x read the power output of the controller. 
 
The controller is operating in heating-only mode and the control requirements are 
handled by the program. These include: 
x defining the high and low temperature values for the operating temperature range 
(The maximum temperature the current Peltier devices can handle is 80 °C), 
x enabling or disable the alarm (In future, two alarms can be used with two 
thermistors while monitoring two different actual temperatures in the system.), 
x defining the high and low temperature values for the low and high alarm 
temperatures. 
 
The LabVIEW program for product temperature controller has been combined with the 
main LabVIEW automation program for simultaneous execution of the pump, staging 
and camera. Initial substrate temperature is set using the user interface of the LabVIEW- 
based automation program. This allows maintaining the temperature of each deposited 
drop at the same initial temperature. For example, during the deposition of a melt-based 
formulation the temperature can be set at 60 °C and the substrate is maintained at this 
temperature during deposition. After the last drop is deposited and the run is finished, the 
LabVIEW program for product temperature control starts to run. It also enables to 
64 
 
 
visually design the temperature profile using the interface shown in Figure 3.9. The initial 
and final temperatures, rate of cooling and duration are specified and the input 
temperature profile is generated.  
 
During process execution, the real time temperature setpoint and actual temperature are 
displayed on the user interface as shown in Figure 3.8. The power output is also 
displayed, which helps the user track the Peltier operation. The times series 
measurements of set point and actual temperatures and power output are saved in the file 
specified by the user. 
 
 
Figure 3.8 Labview program for product temperature control 
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Figure 3.9 Design program for product temperature setpoint profile 
 
3.5 Online Monitoring Strategy 
As mentioned previously, feedback control on a given drop is not possible given the fast 
dynamics of the printing process. Feedback control can only be applied to subsequent 
drops. Therefore, it is important to have several methods of monitoring in order to ensure 
product quality. One way to monitor drops is with imaging.  
 
The ejected drops are monitored using a Manta G-146B camera-based imaging system 
with a Banner D10 photoelectric sensor and an XS40-WHI backlight from Spectrum 
Illumination. Imaging each drop that is formed via LabVIEW allows for the monitoring 
of several aspects of the process. First, it allows the user to closely see each drop 
throughout the process. Second, it is possible to make several conclusions about the 
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process or product just from an analysis of the drop image. Using the LabVIEW program, 
the drop volume, and thus amount of drug per drop, can be calculated. The program also 
calculates the center of the drop within the image so it is possible to track the drop 
trajectory. Although this information cannot be used to remedy anything that happened 
within that drop, the information can then be used in a form of feedback control to adjust 
future drops to return the process to within desired operating bounds.  
The automation program, discussed previously, includes an imaging strategy. First, the 
image is acquired and saved. Using the acquired image, the volume of the drop is 
calculated to determine the amount of API depositing onto the substrate. The image can 
then be analyzed to detect certain process faults, or exceptional events, that may be 
occurring. 
 
3.5.1 Image Acquisition 
A photosensor is used to trigger both the backlight and the camera, so the camera 
captures an image at the same point in the trajectory for each drop. This allows for a 
consistent view of the drop, and also for comparison between sequential drop images. 
The triggering of the camera via the photosensors also allows for the camera code to be 
incorporated into the overall LabVIEW code, but to still run independently of the drop 
deposition and control codes. 
 
After LabVIEW acquires an image, it displays the image on the program interface and 
also saves each image file to a user-defined folder. The image is saved with the file name 
date_time_dropX.jpg, where date and time correspond to date and time of image capture 
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and X corresponds to the number iteration of the loop that contains the camera capture 
code. Essentially, X gives the number of drop in the order of deposition. 
 
3.5.2 Volume Calculation 
By calculating each drop volume and knowing the concentration of the printing solution, 
we can calculate the amount of API in each drop. The volume is found using a “arbitrary 
rotational symmetric shape model” [43]. This method generally works well for 
calculating volumes of drops in flight, as we cannot assume that the drop is a sphere but 
we can normally assume axial symmetry, as seen in Figure 3.10. However, this method 
may be inaccurate if the drop is not circular around its axis but is of a different shape, 
such as ellipsoidal, instead. This can arise with certain types of process faults, such as 
irregular material deposits at the nozzle tip. 
 
 
Figure 3.10 Images of non-uniform drops 
 
This method is based on calculating the diameter in each row or column of pixels in the 
image and then integrating over the entire drop length to find the volume of the drop in 
voxels. Essentially, the method assumes that the drop is a stack of several cylinders with 
different diameters and adds the volume of these cylinders together to find the volume of 
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the whole drop. Then, using a ratio of voxels to volume units, such as microliters or 
picoliters, for the specific camera system, it is possible to calculate the actual volume of 
the drop. The detailed methodology of volume calculation can be accessed in Hirshfield 
et al.(2015) [30]. It is important to note that the volume calculation method was verified 
with both calibration slides and real droplets. The calculated volumes vs known volumes 
(for calibration slides) or gravimetrically determined volumes (for real drops) were 
within 0.33% and 4% error, respectively [30]. 
 
The volume calculated for each drop is recorded in the comma separated values (CSV) 
file and also displayed to the user. Besides being able to use the volume calculations to 
analyze the consistency of drops throughout the process, it is also possible to keep a 
running total of the total volume deposited. For melt-based formulations, this is 
equivalent to knowing the total amount of solids deposited on the dosage form, and thus, 
with the known concentration, it is possible to keep a running total of the amount of drug 
on the form. However, for solvent-based formulations, it is also necessary to know the 
density of the printing material in order to deduce the mass of each drop and thus the 
mass of the solids within the drop. 
 
3.6 Conclusions 
Dropwise Additive Manufacturing for Pharmaceutical Products (DAMPP) is a viable 
system for flexible, on-demand production of dosage forms. The simple unit operations 
and small scale of the prototype allow for more extensive on-line monitoring and real 
time control than can be provided by the traditional batch large-scale pharmaceutical 
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manufacturing methods. However, the drop-on-demand technology does require the 
engineering of specific control strategies to ensure a quality product. The real-time 
process management strategy as described in this chapter encompasses temperature 
control on the reservoir, tubing, pump and substrate and an image monitoring strategy 
that allows for imaging of each drop, calculation of drop volume, and determination of 
the center of drop within the image. The entire process is controlled and automated via 
LabVIEW, allowing for the recording of the complete set of data that corresponds to each 
drop deposited. It bears re-emphasizing that the additional benefit of the real time process 
monitoring system is that not only can deviations be observed but they can be directly 
associated with individual dosages through the Labview data recording system. The 
details of the knowledge management system to complete the data provenance are 
discussed in the next chapter. Consequently tablets deviating from required specifications 
can be tracked, isolated and rejected, providing a form of real time release. In this manner 
the system provides the full provenance of each discrete deposit, and allows for creation 
of a precise final dosage form by controlling and monitoring each drop.  
 
70 
 
 
 A KNOWLEDGE PROVENANCE MANAGEMENT SYSTEM FOR CHAPTER 4.
DAMPP 
4.1 Introduction 
The feasibility of dropwise additive manufacturing of pharmaceutical products has been 
successfully demonstrated both for melt-based and solvent-based formulations, as 
presented in previous chapters [18], [19]. These feasibility studies included a variety of 
solvents and polymers as carriers, active pharmaceutical ingredients (API) and substrates 
such as polymeric films and placebo tablets.  
 
If the DAMPP facility were used to manufacture drug products at a commercial scale 
then the US Food and Drug Administration (FDA), would require detailed information 
about the manufacturing process to support a filing for FDA approval as well as for 
reporting on quality compliance during the actual manufacturing of specific products. For 
example, if one set of drops constitutes one dose, then data would be required to prove, if 
so required by the FDA, that the amount of active in the deposited set of drops is indeed 
within the allowable limits of the prescribed dose for that person. In addition, data for 
other critical quality attributes, such as dissolution rates, would also be required. If the 
facility were used by a compounding pharmacy or clinic for production of a dosage for 
immediate use by patients then too a record of the production to the dosage would be 
needed in order to document that the dosage produced met specifications. In either case, a 
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system is required to record and make accessible the data provenance of each and every 
dosage produced.  
 
To address this need, the DAMPP test bed has the instrumentation to collect a wide range 
of process variables for process monitoring and control as described in Chapter 3. 
Additionally, the test bed was integrated with the Knowledge Provenance Management 
System, KProMS, [63] for the purpose of managing all information generated during a 
run. For a typical run, KProMS is used to set up each production run and store the data 
generated during that run, thereby providing a single point of information access. In this 
chapter, the use of KProMS in managing all aspects of running a DAMPP test bed is 
demonstrated. First, the important parameters for operating a DAMPP test bed is briefly 
described, which is followed by the description of the steps in creating an integrated 
application with KProMS. Then the use of the integrated system for data retrieval and 
analysis is described. 
 
4.2 DAMPP Test Bed Operation 
As a drug product manufacturing system, the DAMPP process must be operated so as to 
assure and document that critical product quality specifications are met. Thus it requires 
precise monitoring and control of the manufacturing operations as well as capture and 
organization of all of the information associated with these operations. The use of 
DAMPP for a new product formulation generally requires execution of two experimental 
phases: determining the range of conditions under which good quality drops are formed 
consistently for that formulation, followed by operation of the manufacturing system 
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under the most desirable operating conditions in that range.  In the case study reported 
here the use of KProMS to support both phases are addressed. 
 
During the DAMPP test bed operation, the input settings associated with all process units 
are specified, which is presented in Section 3.3. The input file contains all the input 
parameter settings, which are required to run the automation program; and it is shown in 
Figure 3.3. The automation program developed in the LabVIEW environment allows 
synchronized execution of the process units. As the first step, a selected drug formulation 
is placed in the materials reservoir. The second step is the IVEK pump, where the 
previously determined best operating conditions are specified: pump rate (RPM), pump 
displacement and volume strokes. Using the precision IVEK pump, the material is ejected 
through the nozzle and deposited on the substrate. The motion sensors detect the drop and 
the camera automatically captures an image of the falling drop. Using real-time image 
analysis, the volume is calculated for each drop and the corresponding dosage amount is 
calculated from the known formulation density and drug concentration. The 
synchronization logic enables the deposition of the drops on the substrate with pre-
defined x - y coordinates, which allows creating a grid-like deposition pattern as well as 
multi-layered drug formulations. After deposition, the substrate temperature controller is 
used to control the cooling temperature profile of the drug deposits, with an Infra-Red (IR) 
camera used to monitor the spatial temperature distribution within the deposit. Both the 
solidification temperature profile and the formulation properties can have an effect on the 
bioavailability of the drug products. Therefore post-processing steps can include different 
quality control tests such as crystallinity measurement or dissolution testing. At the end 
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of a run, the LabVIEW program generates an output file, which is shown in Figure 3.5, 
containing all the process monitoring and control parameters for each drop deposited. 
This includes x - y coordinates, image file name for each drop, drop volume, drop center, 
actual temperature values. Also the drop images, IR images and quality control results are 
saved for each run. 
 
4.3 KProMS System 
A workflow based Knowledge Provenance Management System, KProMS, that functions 
as a HUBzero [64] component has been developed at Purdue University. It captures the 
complete provenance of knowledge by modeling the details of the associated knowledge 
generation steps as a set of hierarchical workflows. Its unique workflow representation 
captures relationships between the steps as a network of nodes connected by material 
and/or information flows. Each data input or output step is represented as a node 
connected by an information flow to the step processing or generating the data. The 
general framework can be used for experimental, scientific and business workflows and 
manufacturing recipes [63]. 
 
4.3.1 Using KProMS 
The use of the KProMS system broadly consists of two steps: the creation of a 
workflow(s) to represent the knowledge generation steps and exercising the workflow(s) 
to create knowledge. A graphical Workflow Builder is used for creating a workflow using 
the following workflow building blocks: workflow; task; subtask; material source, sink, 
input, output and flow; and information input, output and flow. For example, the 
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workflow, named TB3Basic, for modeling the DAMPP system is shown in Figure 4.1.a. 
The icons used in the workflow are explained here: 
 
a. Through the blue TB3Basic workflow icon, the data entry form can be accessed. 
This allows the user to specify necessary information about the run. The data 
entry form is shown in Figure 4.1.b.  
b. The material sources (yellow pentagon: R1 and Subs) represent the formulation 
and substrate used. The data entry form for formulation material source R1 is 
shown in Figure 4.1.c.  
c. A yellow triangle represents material produced. 
d. The workflow consists of the five tasks (green rectangles: Reservoir, IVEK, 
Nozzle, Staging and Cryst) which are described in Section 4.2. The data entry 
form for IVEK pump setup task is shown in Figure 4.1.d. 
e. A camera captures the image of each drop released from the nozzle and an IR 
camera captures the image of drops solidifying on the substrate. The data nodes 
named LabviewData, IRData and CrystData represent the data created by 
Labview, IR camera image files and crystallinity data for the dosage forms, 
respectively. 
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Figure 4.1.a DAMPP system workflow, b. Data entry form for TB3Basic workflow, c. 
Data entry form for Material Source R1, d. Data entry form for IVEK pump setup task 
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4.3.2 Management of the DAMPP Test Bed 
The first step in managing the information related to the DAMPP test bed is to create the 
workflow for the associated processing step as shown in Figure 4.1.a. Each production 
run of the test bed is one instance of the workflow. A production run is associated with 
the set of drops on substrate strips/tablets produced under given set of fixed operating 
conditions. A total of 29 task and subtask parameters define the operating conditions for a 
run, including the set points for pump rpm, number of volume strokes, four temperature 
settings (reservoir, pump, material line and substrate). The set points are used by the 
LabVIEW system, which controls the operation of the system.  
 
The steps in executing a run are shown in Figure 4.2. The PC that runs the system via 
LabVIEW also runs KProMS GUI on the FireFox web browser. After setting up an 
instance using the KProMS GUI, an intermediate text file consisting of the parameters 
defined in the XParForTr data node shown in Figure 4.1.a is downloaded on the PC in a 
specific folder. The Virtual Instrument (VI) created for the system is started and the 
intermediate file is loaded into the VI. The operator confirms that the loaded parameter 
values are correct by observing the user interface of the LabVIEW automation program 
shown in Figure 3.2 and starts the run. The run is executed by LabVIEW via 
communication with the process equipment through the serial and USB ports on the PC 
according to the design of the VI. During the run, LabVIEW creates a tabular text file 
consisting of fixed set of columns. Each row in the file has the following key pieces of 
information about each drop deposited on the substrate: drop volume computed from the 
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processing the drop image captured by the camera, the name of the .png file which has 
the drop image, the x and y coordinates of the drop on the substrate. 
 
At the end of the run, the LabVIEW output file and a compressed file consisting of all 
drop image files are uploaded into the LabViewData data node of the workflow using the 
KProMS GUI. Similarly, crystallinity data and the IR data about a preselected set of 
drops, if applicable, are loaded in the CryData and IRData data nodes of the workflow. 
Thus, a completed run that is stored in the repository has the complete provenance of the 
associated run, including all process parameters and outputs along with the relationships 
defined by the graphical network of the workflow. 
 
 
Figure 4.2 Integration of KProMS and the DAMPP test bed 
 
4.4 Data Extraction and Analysis 
In order to generate useful knowledge from the execution of the process workflow, data 
recorded through the KProMS is extracted and analyzed. A data node in a workflow can 
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have any number of parameters. Each parameter has the following key attributes: name of 
the file in which the associated data is stored and metadata for the data. The metadata can 
be predefined or derived from the file structure. In addition, each piece of information 
stored in the repository using KProMS is accessible with a unique tuple. For example, a 
task parameter is identified by the triplet (Workflow name, task name, parameter 
keyword), a subtask parameter identified by the 4-tuple (Workflow name, task name, 
subtask name, parameter keyword), a column in a data file by the 4-tuple (Workflow 
name, data node name, parameter keyword, column name) and so on.  
 
The knowledge of metadata and a unique identity for each piece of information facilitate 
extraction of data using context sensitive menus. A data node of type Extract Data can be 
incorporated into a workflow to represent data extraction step, which could be part of a 
scientific workflow for analyzing data. An example of a general purpose workflow to 
draw x-y plots is shown in Figure 4.3. 
 
 
Figure 4.3 Scientific workflow for drawing plots 
 
The SelectData node allows specification of the sets of x - y data to extract, for single or 
multiple runs. The data selection process is shown in Figure 4.4. First a template is 
selected, such as TB3Basic:Experimental. Then instances of that template are selected. In 
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this case 6 different process runs, 255 through 260, are selected. Next, the data to be 
extracted is selected. The variables are selected from context sensitive menus to identify 
the 4-tuple associated with it. Here, the columns in a data file are generated from the 
metadata. In Figure 4.4, drop number and drop volume are selected for use in GraphData 
workflow.  
 
  
Figure 4.4 Data selection through SelectData node 
 
The GraphData program of KProMS draws a plot. An example plot is shown in Figure 
4.5.a, where the drop volume vs the drop number is plotted for six different DAMPP 
production runs 255-260. This plot corresponds to the data selection process shown in 
Figure 4.4. Runs 255-257 were performed with a pump rate of 400, pump displacement 
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of 2.5 and volume strokes of 1. These conditions yield an average drop volume of 14.24 
µl. For the runs 258-260, the displacement is 1.5, which decreases the average drop size 
to 9.88 µl.  
 
The KProMS system has a library of programs written in PHP to perform specific 
computational tasks, including: full factorial DOE, linear multiple regression, and basic 
statistics for columns of data such as mean, average, standard deviation and relative 
standard deviation. For the DAMPP run instances the average drop volumes, standard 
deviation and relative standard deviation within each instance and between different 
instances are calculated. The reproducibility of drop sizes is crucial for this process, since 
it directly correlates with the dosage amount. For instances 255-260, the statistics 
calculations are shown in Figures 4.5.b and 4.5.c.  
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Figure 4.5 a. Drop number vs drop volume for instances 255-260, Basic statistics results for instances b. 255-257 and c. 258-260 
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4.4.1 Operating Regime Determination 
Drop quality depends on the drop dynamics which is affected by fluid properties and 
operating conditions. For stable drop formation of a selected formulation, the operating 
regimes should be characterized. For a selected drug formulation, the best operating 
conditions can be determined either using dimensionless numbers as described in Section 
2.2.3 or it can be based on the printing parameters. 
 
4.4.1.1 Operating Regime Based on Dimensionless Numbers 
In order to illustrate the regime of fluid properties where successful drop on demand 
printing can be achieved, the dimensionless numbers such as Re, We and Oh are 
calculated. First, the fluid parameters are measured for two solvent-based formulations 
which either consisting of 30% naproxen and 70% PVP K90,  or  70% naproxen and 30% 
PVP K90 dissolved in ethanol. Measured parameters including the density, surface 
tension and viscosity are listed in Table 4.1. The density is calculated by measuring the 
weight of solution per unit volume. The surface tension is measured with pendant drop 
method and viscosity is measured with a rotating cylinder rheometer (Brookfield 
Engineering Laboratories, Inc., Massachusetts). 
 
Table 4.1 Fluid properties for solvent-based formulations 
 30NAP70PVP 70NAP30PVP 
Density (g/ml) 0.83 0.83 
Interfacial surface tension (mN/m) 24.48 24.14 
Viscosity (mPa.s) 73.90 16.37 
83 
 
 
The fluid velocity is also measured experimentally. At each printing setting, the pump is 
primed for 30 seconds and the volume of the printed drops is measured with a graduated 
cylinder. Three measurements are recorded for each setting and the average value is used 
in the calculations. With the known nozzle diameter and cross sectional area, the fluid 
velocity is calculated.  
 
Next, the Reynolds, Weber and Ohnesorge numbers are calculated using Equations 2.1 to 
2.3 and measured values of velocity, density, nozzle diameter, viscosity and surface 
tension. The drop formation quality information of solvent-based formulation 
30NAP70PVP at various printing settings is presented in Table 4.2 along with the 
measured velocity values and calculated Re, We and Oh numbers. An operating region 
graph using Weber and Reynolds numbers is plotted in Figure 4.6. Although a clear 
distinction between different regions could not be observed, the black arrow demonstrates 
the transition from printable region to the region, where tail and satellite drop formation 
is observed, followed by the region, where there is unsufficient energy for drop formation. 
The outlier points shown in Figure 4.6, might be due to experimental errors while 
measuring various parameters. Similar studies to determine the operating regime using 
the dimensionless numbers has been done for Newtonian fluids [24]. This preliminary 
study demonstrates that a similar operating region can be determined for non-Newtonian 
fluids. However it requires extensive experimental measurement done for each 
formulation at each printing setting. When the operating region is ready for using in the 
DAMPP process, it will be incorporated with the KProMS system. 
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Table 4.2 Dimensionless number calculations for solvent-based formulation Naproxen-
PVPK90 (30:70) 
Drop 
Quality 
Printing 
Settings 
Nozzle 
diameter (mm) 
Velocity 
(m/s) 
Re We Oh 
Printable N17 D2.0 R400 1.15 0.193 2.490 1.449 0.483 
Printable N19 D1.5 R400 0.91 0.281 2.884 2.450 0.543 
Printable N19 D1.5 R500 0.91 0.284 2.915 2.503 0.543 
Tail N17 D2.5 R800 1.15 0.215 2.781 1.807 0.483 
Tail N17 D2.5 R900 1.15 0.208 2.685 1.685 0.483 
Tail N17 D2.0 R800 1.15 0.209 2.698 1.700 0.483 
Tail N17 D2.0 R900 1.15 0.209 2.698 1.700 0.483 
Tail N15 D2.0 R600 1.45 0.126 2.057 0.784 0.430 
Satellite N17 D2.0 R500 1.15 0.192 2.478 1.434 0.483 
Satellite N17 D2.0 R600 1.15 0.197 2.544 1.512 0.483 
Satellite N17 D2.0 R700 1.15 0.206 2.656 1.649 0.483 
Not enough 
energy 
N17 D1.5 R400 1.15 0.173 2.241 1.174 0.483 
Not enough 
energy 
N17 D1.5 R500 1.15 0.178 2.295 1.231 0.483 
Not enough 
energy 
N17 D1.5 R600 1.15 0.178 2.295 1.231 0.483 
Not enough 
energy 
N17 D1.5 R700 1.15 0.181 2.337 1.276 0.483 
Not enough 
energy 
N17 D1.5 R800 1.15 0.181 2.337 1.276 0.483 
Not enough 
energy 
N17 D1.5 R900 1.15 0.178 2.295 1.231 0.483 
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Figure 4.6 Operating regime graph for solvent formulation Naproxen-PVPK90 (30:70) 
 
4.4.1.2 Operating Regime Based on Printing Parameters 
For a selected drug formulation the best operating conditions can be determined 
experimentally. A combination of operating variable values is acceptable if it produces 
good quality drops where good quality drop formation constitutes reproducible formation 
of single primary drop with no tail, satellite drops or spraying. Drop specification criteria 
are demonstrated in Figure 4.7 along with examples of on and off specification drops. 
The images are taken during operating regime determination of various melt-based 
formulations.  
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Drop not within specification due to Drop within 
specification tail satellite drop spraying 
    
Figure 4.7 Drop specification criteria 
 
 
Figure 4.8 Workflow for determining the operating regime 
 
The workflow, named TB3OpRegime, for determining the operating regime for a given 
formulation shown in Figure 4.8. The data node named OperabilityData represents the 
operating regime data created for one combination of nozzle and formulation. An 
instance of this workflow represents an experiment performed to determine the operating 
regime for one combination of formulation, nozzle size and operating temperature. The 
test bed is operated at different settings for pump displacement, pump rate and number of 
volume strokes. The data file associated with the data node has the following four 
columns: Pump rate (RPM), pump displacement, number of volume strokes, drop quality. 
The first three values in each row in the file represent one set of operating conditions, and 
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the last value represents the quality of drops generated (0 for bad drops, 1 for good drops) 
under those operating conditions. 
 
The operating regime data corresponding to the experiment with workflow ID: 382 is 
shown in Table 4.3. The experiment is performed with melt-based formulation consisting 
of 85% PEG3350 and 15% naproxen, and with reservoir, tubing and pump temperatures 
controlled at 87.5 °C, 90°C and 140 °F, respectively. The nozzle N19 is used which has 
an inner diameter of 0.912 mm (19 AWG). In Table 4.3, operating regime data is shown 
only for pump volume strokes of 2. For melt-based formulations containing polymers as 
the carrier, volume strokes 2 is the optimum operating region. However, volume strokes 1 
and 3 are also tested and good drop quality could not be achieved. The data for all 
volume strokes is saved in the OperabilityData node, but it is not shown here. 
 
Table 4.3 Operating regime data for PEG:NAP (85:15) with nozzle N19 and workflow ID: 
382 
Pump rate (0-1000) Pump volume strokes Pump displacement Drop quality 
Number Number Number Number 
300 2 1 0 
400 2 1 0 
500 2 1 0 
600 2 1 0 
700 2 1 0 
800 2 1 0 
900 2 1 0 
1000 2 1 0 
300 2 1.5 0 
400 2 1.5 1 
500 2 1.5 1 
600 2 1.5 0 
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Table 4.3 continued 
700 2 1.5 0 
800 2 1.5 0 
900 2 1.5 0 
1000 2 1.5 0 
300 2 2 0 
400 2 2 1 
500 2 2 1 
600 2 2 1 
700 2 2 0 
800 2 2 0 
900 2 2 0 
1000 2 2 0 
300 2 2.5 0 
400 2 2.5 0 
500 2 2.5 1 
600 2 2.5 1 
700 2 2.5 0 
800 2 2.5 0 
900 2 2.5 0 
1000 2 2.5 0 
300 2 3 0 
400 2 3 0 
500 2 3 0 
600 2 3 0 
700 2 3 1 
800 2 3 0 
900 2 3 0 
1000 2 3 0 
 
Next, the GraphData workflow is used to generate a visual operating region for each 
formulation. In Figure 4.9, for the same experiment with workflow ID: 382, the operating 
region is plotted as a combination of pump displacement and pump rate. With the help of 
this plot, the user can chose from the pump displacement and rates to generate good drops 
at pump volume strokes 2.  
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Figure 4.9 Operating region plot  
 
4.5 Conclusions 
A knowledge management system is essential to record and make accessible the data 
provenance of each and every dosage produced via DAMPP. Therefore, the processing 
steps in the DAMPP system were modelled in the workflow based Knowledge 
Provenance Management System, KProMS. The integration of the automation program 
and KProMS allows inputting all process settings data only once through KProMS and 
successfully running the automation program to execute the process operation. The 
ability to save the output data file, drop images, IR images and crystallinity data after 
each process run allows easy access to all process related online or offline generated data. 
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KProMS is readily and effectively used for managing the data associated with the 
experimental studies. Through statistical analysis of production runs, the experiments are 
compared and the best process conditions are determined for the desired outcome, i.e. 
dosage amount. 
 
Using KProMS, operating regions based on printing parameters are generated for various 
formulations and this knowledge is later used to execute the process workflow with the 
best operating conditions. Operating region can also be presented as a printability region 
based on the dimensionless numbers. In order to develop the printability region 
accurately, extensive experimental data is needed and the fluid parameters should be 
determined for each formulations. Preliminary studies of the printability region are 
presented for solvent-based formulations and in the future it can be extended to melt-
based formulations.  
 
KProMS was used by a group of undergraduate researchers to run DAMPP process 
during their summer internships. It enables the users to build a consensus during their 
experimental studies by providing a logical structure to organize, store and retrieve data 
and by allowing easy access to the generated knowledge.  
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 SUPERVISORY CONTROL OF DAMPP: EFFECT OF CRITICAL CHAPTER 5.
PROCESS PARAMETERS ON PRODUCT QUALITY OF MELT-BASED SOLID 
ORAL DOSAGES‡ 
5.1 Introduction 
For the dropwise additive manufacturing system, the desired critical quality attributes 
(CQA) of the dosage forms that should be kept within the appropriate limits are the 
dosage amount and drug morphology. The critical process parameters (CPP) that have a 
direct impact on the CQA’s are the drop size, product and process temperatures. This 
chapter presents a supervisory control system implemented on the drop on demand 
manufacturing process which manipulates these CPP’s with the goal of ensuring that the 
CQA’s are maintained within specified limits. This control system is based on the RTPM 
strategy discussed in Chapter 3, which consists of on-line monitoring, automation and 
regulatory control. These principles are essential for producing individual dosage forms 
with the desired critical quality attributes.  
 
First, the supervisory control framework is presented which serves to control critical 
process parameters such as product temperature and drop size. Then, the effects of 
process parameters on the final product quality are investigated and the resulting melt-
                                                 
‡ This chapter is based on: E. Içten, A. Giridhar, Z. K. Nagy, and G. V Reklaitis, “Drop-
on-Demand System for Manufacturing of Melt-based Solid Oral Dosage: Effect of 
Critical Process Parameters on Product Quality,” AAPS PharmSciTech, doi: 
10.1208/s12249-015-0348-3, 2015. 
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based pharmaceutical dosage forms are characterized using various techniques, including 
Raman spectroscopy, optical microscopy with a hot stage and dissolution testing. 
 
5.2 Supervisory Control Framework 
The supervisory control framework applied to the DAMPP is shown in Figure 5.1. It 
consists of a network of PID loops controlling the process and product temperatures 
while executing camera, pump and staging simultaneously. This framework enables 
control of the CPP’s to achieve the desired CQA’s, which are listed in Table 3.1. The 
dosage amount is determined from the drop size and the known formulation composition. 
The product solid state depends on the formulation composition, on the selection of the 
substrate and on the CPP’s, i.e. product temperature and drop size. The selection of the 
polymer used in the formulation can change the morphology by promoting or inhibiting 
crystallization of the drug [32].  
 
The product temperature corresponds to the crystallization temperature of the deposited 
drops. The crystallization temperature profile has a strong effect on product solid state 
and morphology, which influence the dissolution properties and hence the bioavailability 
of the drug. In bulk crystallization, a controlled temperature profile followed through the 
crystallization process can affect the final product properties [27], [48], [65]. Similarly, 
by manipulating the substrate temperature profile using varying temperature gradients, 
the drop solidification process can be controlled [28]. Since the drop size also affects the 
drop solidification process by changing the heat transfer dynamics, precise control of the 
drop solidification process occurring on the substrate is critical. In the DAMPP process, 
93 
 
 
the crystallization temperature of the deposited drops is controlled via the Peltier devices 
placed underneath the substrate on the xy-staging. The substrate temperature control via 
Peltiers is implemented through a PID loop. Programmed temperature gradients, 
including step changes, ramping heating or cooling, cycling or any combination of these 
temperature profiles, can be applied to the drug deposits using the LabVIEW based 
automation of the substrate temperature control system. As in the case of bulk 
crystallization processes, cycling of temperature also can be an effective mechanism for 
control of crystal size, thus controlling feature granularity [66], [67].  
 
 
Figure 5.1 Supervisory control framework for DAMPP. TC: temperature controller, TT: 
temperature transmitter. 
 
5.3 Production of Dosage Forms with Different Critical Process Parameters 
In order to study the effects of critical process parameters on the product solid state and 
morphology, dosage forms of melts were produced using two different drop sizes by 
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applying different substrate temperature profiles. In this study, naproxen and PEG 3350 
were chosen as the model API and polymer. The preparation of the formulation and 
substrate films were explained in Chapter 2. The dosage forms consisted of 15% 
naproxen and 85% PEG 3350 by weight. The formulation was co-melted at 65°C, at 
which temperature the polymer melts and the drug dissolved in the molten polymer. The 
temperature of the system was controlled at 70°C throughout the process. The molten 
formulation was subjected to the operating temperature of 70°C during the maximum 
residence time of 5.4 min, which was achieved with the slowest production rate. In 
Chapter 2, the chemical stability of naproxen during production was investigated via 
HPLC experiments, which showed that the drug found in the dosage forms was stable for 
at least 15 min under the same operating conditions. Since the dosage forms were created 
and analyzed within a matter of minutes, varying ambient conditions, such as relative 
humidity, were not impactful on the results. 
 
Two different drop sizes are used to produce the dosage forms with target dosage of 15 
mg of API. The different drop sizes are obtained by changing the pump settings such as 
displacement, volume strokes, and rate as well as nozzle size. For simplicity, the drops 
with different sizes will be referred as ‘small’ and ‘large’ drops. The reproducibility of 
the dosage forms are analyzed gravimetrically as described in Chapter 2. The 
reproducibility results are shown in Table 5.1. A relative standard deviation (RSD) of less 
than 6% is achieved for melt-based dosage forms produced for this study. These dosage 
forms were produced before the nozzle holder and the air heating system has been built. 
Therefore, a single diameter of 1.65 mm was used as the nozzle and the different drop 
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sizes were achieved by changing the pump printing parameters. In Chapter 2, lower RSD 
values (less than 2% for most cases) has been reported, where the new nozzle holder and 
air heating system was used.  The number of drops to be printed on the HMPC-PEG films 
was adjusted depending on the drop size to reach the proper dosage amount. Dosage 
forms were produced by printing either ‘large’ drops of size 23.4 mg with a standard 
deviation of 1.4 mg or ‘small’ drops of size 19.4 mg with a standard deviation of 0.3 mg 
on HPMC-PEG films as the substrate.  
 
Table 5.1 Reproducibility analysis of dosage forms 
Drop Size Average Dosage Amount (mg) RSD (%) 
Small 14.56 1.71 
Large 14.27 5.74 
 
5.4 Analysis of Melt Based Solid Oral Dosages 
5.4.1 Raman Microscopy: Crystallinity Study  
The crystallinity of the melt formulations consisting of 15% naproxen and 85% PEG 
3350 was studied using Raman microscopy: Raman RXN1 Microprobe (Kaiser Optical 
Systems, Michigan). First the spectra of pure naproxen and PEG 3350 solid dispersions 
were obtained. Naproxen and PEG 3350 powders were heated above their melting 
temperatures, to 160 °C and 60 °C, respectively. The melts of pure naproxen and pure 
PEG 3350 were solidified at room temperature and then analyzed to obtain the spectra of 
pure compounds. The spectra of the melt formulation consisting of 15% naproxen and 85% 
PEG 3350 were obtained by analyzing the drops of the melt formulation deposited using 
the dropwise additive manufacturing process. 
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Figure 5.2 Raman spectra of a. pure NAP, b. pure PEG 3350, c. co-melt of NAP-PEG 
3350 (15:85). Characteristic peaks at 760 and 1280 cm-1 are shown with red and blue 
arrows, respectively. 
 
Raman spectra of pure naproxen melt, pure PEG 3350 melt and melt-based drug deposits 
of NAP-PEG 3350 (15:85) are presented in Figures 5.2.a, 5.2.b and 5.2.c, respectively. 
The characteristic peaks of pure naproxen and pure PEG 3350 at 760 cm-1 and 1280 cm-1 
are used for the analysis. Raman spectra of the dosage forms confirm that naproxen 
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present in the dosage forms is crystalline, which is in accordance with x-ray diffraction 
analysis of the same formulation reported in Chapter 2 and by [19].  
 
5.4.2 Raman Mapping: Distribution of API throughout the Drop 
The drug distribution throughout the deposited drop is analyzed using Raman mapping 
employed for the dosage forms. Different areas throughout the drop deposits were 
analyzed (data not shown). A color intensity Raman map was built based on the ratio of 
the characteristic peaks of naproxen and PEG 3350. In Figure 5.3, a representative area 
(660 µm × 1000 µm) of the drop deposits is mapped with 100 µm step sizes. The scale on 
the right hand side represents the ratio of the characteristic peaks of naproxen and PEG 
3350 at 760 cm-1 and 1280 cm-1, respectively. The small relative intensity differences 
confirm that naproxen has an even distribution throughout the drop. This finding is in 
accordance with HPLC analysis conducted on the melt-based formulations, which 
suggested that the amount of drug recovered from each drop was the same as the amount 
present in the drug formulation [19]. Here it is shown that in a sample area of the drop, 
the drug is distributed well within the polymer matrix. Raman measurements performed 
over different areas of the droplet indicated similarly homogenous drug distribution.   
 
5.5 Effect of Crystallization Temperature Control on Product Solid State 
Since the crystallization temperature of the drug deposits has an effect on the product 
solid state and morphology, precise control of the drop crystallization and solidification 
processes is crucial to reach the desired product quality. In the DOD system, different 
programmed cooling temperature profiles were applied to the substrates containing the 
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Figure 5.3 Raman map of melt-based deposits of NAP-PEG 3350 (15:85). Map Area 600 
µm x 1000 µm. 
 
drug deposits. Specifically, in this study four different temperature profiles were designed 
and applied via the Peltier devices placed underneath the substrate. The molten deposits 
were cooled from 60 °C down to 30 °C using different temperature profiles, which are 
shown in Figure 5.4. A constant temperature profile is achieved by printing the drops 
onto films maintained at 30 °C and by controlling its temperature at 30 °C until the drops 
are solidified. The other dosage forms were printed onto films maintained at 60 °C and 
cooled down to 30 °C using: a fast cooling rate of 10 °C/min; or a slow cooling rate of 
1 °C/min; or by applying heating/cooling cycles where the dosage forms were cooled 
with repeated cycles of cooling with a rate of 10 °C/min for one minute followed by 
heating with a rate of 1 °C/min for one minute until the deposit reached 30 °C.  
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In order to study the crystallization of the drug within the dosage forms under different 
temperature profiles, optical microscopy experiments are performed with a hot stage 
following the cooling temperature profiles shown on Figure 5.4. A Zeiss Axio Imager 
A2m polarized light microscope (Carl Zeiss Microscopy, LLC, NY) equipped with a 
Linkam THMS 600 hot-stage (Linkam Scientific Instruments Ltd., Surrey, UK) was used 
for this study. The naproxen and PEG 3350 were physically mixed in (15:85) weight ratio 
and heated to 65 °C until completely melted. After a homogeneous melt was formed, it 
was cooled down to 30 °C with the different cooling rates shown in Figure 5.4. 
 
 
Figure 5.4 Temperature profiles applied on the substrate 
 
Although there were no differences observed in the crystallinity of the dosage forms, the 
application of different temperature profiles did in fact change the crystallization 
behavior and morphology. The induction times for crystal formation showed differences 
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based on the temperature profile applied. Using the images recorded via hot-stage 
microscopy, the induction time and temperatures corresponding to the first nucleus 
formation were determined. In Figure 5.4, the induction times are shown with the points 
marked on the fast cooling, slow cooling and cycling temperature profile curves. The 
measurements were taken in replicates to determine the mean induction temperatures and 
times, and the corresponding standard deviations are listed in Table 5.2. Under the fast 
cooling profile, the induction occurs at 36.6 °C in 4.3 min. Under cycling and slow 
cooling temperature profiles, the average induction temperatures are 42.0 °C and 45.6 °C 
occurring in 6.4 min and 16.4 min, respectively. These results indicated that instead of 
applying slow cooling for 16.4 min, a designed temperature cycle can be applied to 
shorten the induction time by keeping the induction temperature, hence crystallization 
behavior, similar. 
 
Table 5.2 Induction points when different temperature profiles are applied 
 Fast Cooling Cycling Slow Cooling 
Induction Temperature (°C) 36.6 ± 1.5 42.0 ± 0.8  45.6 ± 1.5 
Induction Time(min) 4.3 6.4 16.4 
 
In addition to the differences observed in the crystallization behavior, morphological 
differences are also observed between the dosages solidified under different temperature 
profiles using optical microscopy with a hot stage. When the melts are cooled down with 
the fast cooling rate of 10 °C/min, surface defects are observed, which are shown in 
Figure 5.5.a. This is mainly due to the fact that fast cooling resulted in more nucleation 
sites during crystallization, thus producing higher surface area of crystals. 
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Figure 5.5 Optical microscopy images of melt-based deposits (Naproxen-PEG 3350) after 
a. fast cooling, b. slow cooling, c. cycling. 
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When the melts are cooled down with the slow cooling rate of 1 °C/min, surface defects 
were reduced, however they were still observed as shown in Figure 5.5.b. When the melts 
were subjected to the cycling temperature profile, the surface defects were eliminated, as 
shown in Figure 5.5.c. With designed cycles and through repeated partial re-melting and 
solidifying the dosage forms, alternative morphology changes can be obtained. 
 
5.6 Effect of Critical Process Parameters on the Dissolution of Dosage Forms 
The crystallization temperature profile applied to the drug deposits affects both the 
crystallization behavior and the morphology of the drug, which are known to influence 
both the dissolution behavior and bioavailability of the drug. Therefore, dissolution 
testing was performed to study the effect of the substrate temperature profile and also the 
effect of the drop size on the dissolution properties of the drug. Dissolution testing is 
performed as described in Chapter 2. Dosage forms of melts containing 15% naproxen 
and 85% PEG 3350 were produced using small and large drop sizes by applying different 
substrate temperature profiles.  
 
First, the effect of substrate temperature profile was studied and the dissolution behaviors 
of the dosage forms produced with the same drop size and following different cooling 
profiles were compared. The dissolution profiles of the dosage forms, which are produced 
with small drop size and solidified using fast or slow cooling rates, are compared in 
Figure 5.6. When the fast cooling rate of 10 °C/min is applied to the dosage forms 
containing small drops, faster dissolution is observed than is seen with samples produced 
with the slower cooling rate of 1 °C/min. The dissolution profiles of the dosage forms, 
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which are produced with large drop size and solidified using fast or slow cooling rates, 
are compared in Figure 5.7. Similar to the behavior of the dosage forms containing small 
drops, faster dissolution is observed when the fast cooling rate of 10 °C/min is applied to 
the dosage forms containing large drops. During fast cooling, more nucleation sites are 
created that result in higher surface area, which was also observed with hot-stage 
microscopy experiments, and therefore in faster dissolution of the dosage forms. 
 
 
Figure 5.6 Effect of different cooling profiles on the dissolution of the dosage forms 
created with small drops. 
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Figure 5.7 Effect of different cooling profiles on the dissolution of the dosage forms 
created with small drops. 
 
The effect of the drop size was further investigated and the dissolution behavior were 
compared for the dosage forms containing either large or small drops under the same 
crystallization temperature profiles. When the temperature of the drug deposits 
containing either small or large drops are controlled at a constant temperature of 30 °C, 
significant variation of the dissolution profiles are observed both within the dosage forms 
of the same drop size and between the dosage forms containing different drop sizes. This 
variation is evident from the error bars shown in Figure 5.8.a. When the substrate 
temperature is held constant, then the cooling profile within the droplets is influenced by 
their volume, which can result in significant variations in the crystallization conditions. 
While control of the temperature of the deposits was exercised by manipulating the 
temperature of the surface of the Peltier, the temperature within a deposit is non-uniform.  
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Indeed infra-red camera images of melt-deposits solidifying at room temperature, shown 
in Figure 5.9, indicate that there are temperature gradients present within the drops.  
 
 
Figure 5.8 Dissolution profiles of the dosage forms created with two different drop sizes 
and solidified at different temperature profiles: a. constant temperature, b. fast cooling, c. 
slow cooling, d. cycling. 
 
However, when the drug deposits are solidified by applying a fast cooling rate of 
10 °C/min; the temperature gradient within the dosages containing the same drop size 
decreases significantly. Thus, this results in smaller variation in the dissolution profile for 
the dosage forms containing the same size of droplets, which reflected in the reduced 
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error bars shown in Figure 5.8.b. In the case of solidification of dosage forms by applying 
a slow cooling rate of 1 °C/min, the differences in the dissolution profile of the dosages 
containing both the same drop size and different drop sizes decrease further, as shown in 
Figure 5.8.c. The use of the slow cooling profile minimizes the differences due to drop 
size by enabling better heat transfer and thus minimizes the spatial distribution of 
temperature differences.  
 
 
Figure 5.9 Infrared camera image of melt-based deposits solidifying at room temperature 
 
Finally, the effect of cycling of the substrate temperature on the dissolution profile was 
studied. The effect of the drop sizes used can be seen in terms of the different dissolution 
rates. There are small variations in the dissolution of the dosages produced with the same 
drop size as represented by reduced error bars in Figure 5.8.d. Cycling of temperature is 
also an effective mechanism for the control of crystal morphology as further discussed in 
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the previous section. Designed cycles can be used to eliminate surface defect and achieve 
morphological changes by repeated partial re-melting and solidifying the dosage forms. It 
can also be used to reduce the time for crystallization and achieve a similar crystallization 
behavior. 
 
Since pharmaceutical products must meet the target bioavailability regardless of their 
dosage amount, knowledge of the effect of the process conditions on the dissolution of 
the drug is of utmost importance. Thus by applying an appropriate cooling profile the 
differences due to drop sizes can be minimized and a desired dissolution rate can be 
achieved for dosages with different drop sizes.  
 
With the model formulation used in this study, the amorphous form of naproxen is not 
produced in the presence of PEG 3350, since it actually promotes crystallization of 
naproxen. However amorphous forms can be produced with alternative choice of 
polymers, which inhibit crystallization, along with suitable choice of operating conditions. 
It is well known that the dissolution of low-solubility drugs can be enhanced, by 
producing product forms in which the active is in amorphous forms. However since 
stability of amorphous drug forms can be challenging, design of crystallization 
temperature profile and precise control of substrate temperature profile are even more 
important than in the case of crystalline API formulations.  
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5.7 Conclusions 
In this chapter, a supervisory control system implemented for the dropwise additive 
manufacturing process is reported which has as its goal ensuring reproducible production 
and final product quality. The effect of the critical process parameters, such as drop size 
and product and process temperatures, on the final product quality, namely dosage 
amount and drug morphology, is investigated and the produced melt-based 
pharmaceutical dosage forms are analyzed. Dosage forms of melts containing the model 
formulation of naproxen and PEG were produced using small and large drop sizes by 
following selected substrate temperature profiles, including cooling ramping profiles, 
constant temperature and temperature cycling. The presented crystallization temperature 
control strategy is used to tailor the crystallization behavior of drug deposits and to 
achieve consistent drug morphology. Hot-stage microscopy studies prove that the 
different product morphologies can be achieved by controlling the cooling profile. The 
results indicate that by applying controlled temperature cycles on the deposits, the desired 
drug morphology and crystallization behavior can be achieved. Moreover, melt-based 
dosages of smaller drops have faster dissolution compared to melt-based dosages of 
larger drops with the same dosage amount. Thus, the supervisory control strategy can be 
used to monitor the drop size online and to predict a crystallization temperature profile 
for the monitored drop size such that the desired bioavailability of the drug is achieved 
and variations in the dissolution profiles due to variable dosage amount are mitigated. 
Such a process control strategy is developed and presented in the next chapter. Hence, it 
enables the application of the drop on demand system for the production of 
individualized dosage regimens for personalized treatments. 
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Although the use of PEG in the formulation enhances the dissolution of naproxen, the 
API present in the melt-based formulation is in crystalline form. Solubility of APIs can 
be enhanced further by using the active ingredient in the amorphous form which is 
discussed in Chapter 8. Amorphous forms can be stabilized through designed temperature 
profiles, which can be then controlled and applied with the supervisory control system. 
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 PROCESS CONTROL OF THE DROPWISE ADDITIVE CHAPTER 6.
MANUFACTURING SYSTEM USING POLYNOMIAL CHAOS EXPANSION 
BASED SURROGATE MODEL§ 
6.1 Introduction 
The development of a supervisory control framework on DAMPP, including on-line 
monitoring, automation and closed-loop control, is presented in the previous chapter. The 
effect of the critical process parameters on the final drug property is investigated and it is 
shown that implementation of a supervisory control system on the process is essential for 
producing individual dosage forms with the desired critical quality attributes. This 
chapter presents an improved process control framework, which assures precise control 
of formulation composition, drop size, deposit morphology and drug dissolution [68].  
 
In order to achieve proper product morphology, a data driven approach based on 
polynomial chaos expansion (PCE) is used to relate the critical process parameters to 
deposit morphology using dissolution data of the active pharmaceutical ingredient. The 
dissolution testing is a standardized off-line laboratory procedure widely used as 
indicator of bioavailability. The PCE-based surrogate model is then used in an optimal 
control framework to determine the required temperature profile to achieve a desired 
                                                 
§ This chapter is based on: E. Içten, Z. K. Nagy, and G. V. Reklaitis, “Process control of a 
dropwise additive manufacturing system for pharmaceuticals using polynomial chaos 
expansion based surrogate model,” Computers & Chemical Engineering, vol. 83, pp. 
221–231, 2015. 
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bioavailability. In pharmaceutical manufacture, the preferred product quality targets are 
those closer to reflecting the performance of the product in the patient, such as 
dissolution, than are traditional quality metrics, such as composition. As noted in recent 
FDA publications [69], the ultimate goal is real time release of product, that is, by 
passing of the traditional laboratory-based quality control step, such as dissolution testing, 
through use of measurement and advanced control methods during manufacture so as to 
allow product to be ready for release to the market immediately upon manufacture. The 
process control strategy reported in this chapter is novel not only in providing effective 
control of the drop on demand manufacturing process but also is one of the first efforts in 
the literature demonstrating elements of model-based real time release (MBRTR) and the 
concept of quality-by-control (QbC), whereby product performance and consistent 
quality are achieved by the design of suitable control strategies. 
 
6.2 Process Control Strategy 
The process control strategy for the dropwise additive manufacturing process is shown in 
Figure 6.1. The control strategy consists of two main parts: a supervisory control system 
and a surrogate model based hierarchical control layer. The supervisory control system is 
described in Chapter 5 along with the effect of CPP’s on the quality attributes of drug 
products. The supervisory control system provides effective control of the drop on 
demand manufacturing process, whereas the surrogate model based hierarchical control 
layer demonstrates the indirect control of drug dissolution online and enables model-
based real time release of solid oral dosages.  
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Figure 6.1 Process control strategy for DAMPP 
 
6.2.1 Surrogate Model-based Hierarchical Control System 
A surrogate model-based hierarchical control system is implemented on top of the low-
level control system to ensure that the drug products have the desired product 
morphology regardless of their dosage amount, i.e. drop size. This can be achieved by 
monitoring the drop size via the online imaging system and manipulating the temperature 
profile applied on the substrate for the measured drop size to ensure consistent quality 
attributes. The crystallization temperature profile has a strong effect on product solid 
state and morphology, which influence the dissolution performance of the drug.  
 
In the pharmaceutical industry, drug dissolution testing is performed as a standard 
requirement to provide critical in vitro drug release information for quality control 
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purposes of solid oral dosage forms. The effectiveness of solid oral dosage forms relies 
on the drug dissolving in the fluids of the gastrointestinal tract prior to absorption into the 
systemic circulation. The rate of dissolution of a dosage form therefore influences the 
amount of drug available to the body, i.e. its bioavailability. Since inadequacies in 
bioavailability can result in ineffective or excessive treatment, precise control of the drop 
solidification process occurring on the substrate is critical.  
 
In order to optimize the temperature profile applied on the substrate, a data driven 
modelling approach is used which relates the temperature profiles to the dissolution 
properties of the drug as a measure of product quality. With this approach, consistent 
dissolution profile can be achieved for drug products containing different drop sizes. The 
effect of critical process parameters on product quality is investigated in Chapter 5. It is 
shown that the differences in the drop size create a cooling temperature gradient within 
the drop deposits, which affects the dissolution properties of the drug. This knowledge is 
used to build a surrogate model-based control system, which is described in Section 6.3, 
and to optimize the temperature profiles as outlined in Section 6.4. 
 
6.3 Polynomial Chaos Expansion Based Surrogate Model Development 
Due to the nonlinear behavior of the solidification and crystallization processes occurring 
within the melt drops and due to the presence of disturbances, the typical linear data 
driven modeling approaches may be challenged in relating the crystallization temperature 
profiles to the dissolution profile with acceptable accuracy. A methodology based on 
nonlinear data driven modelling approaches such as artificial neural networks (ANN) or 
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polynomial chaos expansions (PCE) can be used to develop a surrogate model describing 
this system. A surrogate model can be thought of as a “regression” to a set of data, where 
the data is a set of input–output pairings obtained by evaluating a black-box model of the 
complex system [70], [71]. Maintaining fidelity while being computationally economical 
are the main aspects to consider while choosing a surrogate model for a certain 
application [72].  
 
ANNs are mathematical models consisting of interconnected simple processing units, 
known as neurons, represented in input-output layers along with hidden layer(s) [73].The 
parameters of a network include weights and biases, and the operation performed at each 
neuron. The problem of fitting these parameters is known as training the network. One 
disadvantage of ANNs is the need for selecting the number of neurons, which must be 
sufficiently high to capture functional behavior but not so high as to cause overfitting 
[71]. In the case of a limited number of experimental data, capturing functional behavior 
can be a challenge. Another disadvantage of ANNs is that there are no mechanisms for 
taking into account the nature of the distribution functions of the uncertainties in the data. 
 
Polynomial chaos is a type of spectral method with useful properties that can be exploited 
for the computations of surrogate model generation and parameter determination [74]. 
Polynomial chaos expansion was introduced by (Wiener, 1938) for turbulence modeling 
[75] and it became popular only in the last few decades after the surge of fast computers 
with parallel computing ability [74]. The implementation of PCEs in terms of Hermite 
polynomials for linear elastic problems [76] started broadening the application area of 
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this method. More recently, since the discovery of the possible uses of PCE to define the 
uncertain model as a deterministic model with an extended number of variables, PCE has 
been applied in a large variety of disciplines [77]. Its application areas include 
computational fluid dynamics [78], robust design problems [79] and chemical processes 
[77], [80]. 
 
In this work, a methodology based on polynomial chaos expansion (PCE) containing 
orthogonal basis with respect to the Gaussian probability measure is used to develop a 
surrogate model [74]. PCE can be used to replace a nonlinear system with a surrogate 
model that adequately describes the input to state and input to output behavior [80]. PCE 
offers three main advantages: small number of parameters hence efficiency in using 
experimental data, ability to incorporate information about parameter uncertainty and an 
expansion structure which allows convenience incorporation of additional nonlinear 
teams if the data requires it. If the parameter uncertainties are described in terms of 
standard normal random variables, the PCE can describe the model output \  as an 
expansion of multidimensional Hermite polynomial functions of the uncertain parameters 
T  [80]. Using the Hermite bases in the PCE, the output can be expressed in terms of the 
standard random normal variables iT  using an expansion of order d :  
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where nT is the number of parameters and 1 1 2 1 2 3
( ) ( ) ( ), , ,...d d di i i i i ia a a are deterministic coefficients 
in R to be estimated [80]. The multidimensional Hermite polynomials of degree 
11 2
, ,..., , ( ,..., )n m i mm i i i T T T * are 
 
1
1/2
1/2
1
( ,..., ) ( 1)
...
T
T
m
m
m i m
m
ee
T T
T TT T T T
w*   w w
 Eq. 6.2 
 
The number of coefficients N in the PCE depends on the number of uncertain parameters 
and the order of expansion. It can be calculated as 
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For most engineering applications, the use of third or fourth order expansion is sufficient. 
However, the determination of the most appropriate number of terms to be used in the 
expansion needs to be made for each application. For instance Nagy and Braatz (2007) 
reported that a second order model was sufficient in the case of a batch crystallization 
process application and thus that the use of third order PCE model was not required [80]. 
The use of high order expansion increase the number of coefficients required for the 
model development. In the case of limited number of experimental data available, lower 
order PCE models are preferred. 
 
The polynomial chaos expansion is convergent in the mean-square sense [76]. Therefore 
the coefficients in the PCE 
1 1 2 1 2 3
( ) ( ) ( ), , ,...d d di i i i i ia a a can be calculated using least square 
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minimization by considering sample input-output pairs from the model to achieve the 
best fit between the surrogate PCE model and the experimental data [80]. The initial 
coefficients in the PCE are selected randomly. Since the initial coefficients affect the 
accuracy of the calculations, the coefficients from the previous solution are used to 
perform the least square minimization iteratively until there is no significant difference 
between the predicted outputs. In this manner, the best PCE parameters can be 
determined. The steps of the surrogate model development using PCE are shown in the 
flowchart in Figure 6.2. 
 
 
Figure 6.2 PCE based surrogate model development 
 
This computationally efficient method is used to generate a data driven input-output 
model relating temperature control profiles and the dissolution profiles of the dosage 
forms produced with the dropwise additive manufacturing process. In the pharmaceutical 
industry, it is common practice to treat the uncertainties in dissolution data as normally 
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distributed [81]. Moreover, uncertainties in temperature measurements via thermocouples 
are generally accepted to have normal distributions. Consequently, normal distribution on 
the model input data is assumed and therefore orthogonal Hermite polynomials are used 
in the PCE model. However if the uncertainties are not normally distributed, then 
different orthogonal polynomials with different distribution types can be used in PCE 
model development, including Jacobi, Legendre, Laguerre and Chebyshev polynomials 
[74].  
 
 
Figure 6.3 Input-output pairs for (1-1) and (5-1) PCE-based surrogate models 
 
In Figure 6.3, two different representations of the model inputs, i.e. temperature profiles, 
and the model outputs, i.e. dissolution profiles, are shown. Different PCE models can be 
developed with different numbers of input data, which are required to describe the system 
accurately. In Figure 6.3.a, (1-1) PCE model representing single input-single output case 
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is shown. For (1-1) PCE model, the temperature control profiles are described with a 
single input data representing the linear cooling rate applied to the drops. In Figure 6.3.b, 
(5-1) PCE model representing multiple input-single output case is shown. For (5-1) PCE 
model, the temperature control profiles are represented as the temperature values 
corresponding to discrete times. These time values are selected to ensure distinct 
discretization between different temperature profiles.  
 
In addition to better accuracy, another advantage of the (5-1) PCE model is that more 
complex temperature trajectories can be included in the hierarchical control scheme, not 
only linear cooling, enabling better control of the dissolution profile. The output data is 
calculated as the characteristic time constant W  corresponding to time to reach 60 % of 
total dissolution, which would be an approximation of the time constant of the dissolution 
profile, approximating the dissolution process with first order dynamics. Eq. 6.4 gives the 
functional input-output representation for the (1-1) PCE model,  
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where ia  are the PCE coefficients, 1( )iT* are the first degree Hermite polynomials, and 𝑅 
is the linear cooling rate applied to the drops. Eq. 6.5 gives the functional input-output 
representation for the (5-1) PCE model, 
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where ia  are the PCE coefficients, 1( )iT* are the first degree Hermite polynomials, and 
𝑇𝑛𝜃 are the discretized temperature values.  
 
As a case study, dosage forms of melts containing 15 mg of API were produced by 
depositing 5 drops with the average size of 18.6 mg with a standard deviation of 0.6 mg. 
The average drop sizes and the corresponding standard deviations are calculated based on 
21 replicates of dosage forms. The same model formulation, substrate and process 
temperatures are used throughout the process as described in Chapter 5. After the 
deposition, different controlled cooling profiles, which are shown in Figure 6.4, are 
applied to the dosage forms with 3 replicates at each condition.  
 
The corresponding dissolution profiles are used to test a 1st order PCE with different 
number of input parameters. Single value cooling rates are used as the single input 
parameters for (1-1) PCE model. Discretized cooling profiles are obtained by using the 
temperature values corresponding to 0, 2, 10, 30, 60 minutes during cooling and are used 
as multiple input parameters for (5-1) PCE model. Depending on the number of input 
parameters, different numbers of coefficients are required to build the model. In this case 
study, 𝑁 = 2 and 𝑁 = 6 coefficients are used for the PCE models with single input (1-1) 
121 
 
 
121 
and with multiple input (5-1), respectively. The single input, i.e. cooling rates, and 
multiple input, i.e. discretized temperature profiles, along with the output data, i.e. the 
time constants of the dissolution profiles, used in the model development are listed in 
Table 6.1.  
 
 
Figure 6.4 Crystallization temperature profiles used in the PCE model development 
 
Next, the PCE models are subjected to leave-one-out cross-validation and resampling to 
get a better comparison on the prediction capability of the single input (1-1) and 5 input 
(5-1) PCE models. Here validation data both within and outside the range of training data 
are used. For both models, the mean square error of estimation (MSEE) and mean square 
error of prediction (MSEP) are calculated and shown in Table 6.2. The model fit and 
prediction capabilities of the (1-1) PCE model and the (5-1) PCE model are shown in 
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Figure 6.5.a and 6.5.b, respectively. The average residuals of (1-1) and (5-1) models are 
15.0% and 4.4%, respectively. The (5-1) PCE model provides better prediction than the 
(1-1) PCE model both with lower residuals and with lower MSEE and MSEP values.  
 
Table 6.1 Single input, multiple input, single output parameters for PCE based model 
development 
Cooling Rates Discretized Temperature Profiles Dissolution Time Constants W  
15 °C/min [60 30 30 30 30] 8 min 
10 °C/min [60 40 30 30 30] 8.8 min 
3 °C/min [60 54 30 30 30] 9.6 min 
1.5 °C/min [60 57 45 30 30] 10.2 min 
1 °C/min [60 58 50 30 30] 10.7 min 
0.75 °C/min [60 58.5 52.5 37.5 30] 11.5 min 
0.5 °C/min [60 59 55 45 30] 18.4 min 
 
Table 6.2 Mean square error of estimation (MSEE) and prediction (MSEP) values for 
single input (1-1) and multiple input (5-1) PCE based models 
 
1-1 PCE Model 5-1 PCE Model 
Mean Square Error of Estimation 6.33 0.72 
Mean Square Error of Prediction 11.62 7.05 
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Figure 6.5 Performance of 1st order PCE model with validation and prediction for a. single input single output (1-1), b. multiple input 
single output (5-1) cases. Exp data: experimental data points used in PCE development, PCE: model validation points, Actual: the 
experimental time constant, which is predicted using the PCE model, Simulated: the model prediction 
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6.4 Surrogate Model Based Optimization of Temperature Profiles 
After validation, both of the PCE models, i.e. (1-1) and (5-1) PCE models, are used to 
determine the optimal temperature profiles needed to reach the desired process outcome, 
i.e. time constant W  of the dissolution profile. The predicted temperature profiles using 
different models are compared qualitatively. The data points which are left out for cross 
validation are used in the prediction of the temperature profiles.  
 
The optimal control formulation based on the (1-1) PCE model used in the higher level 
supervisory controller is given by Eq. 6.6. The minimum and maximum temperature 
cooling rates are  min 0.5 / minCR  q  and max 15 / minCR  q , respectively. The average 
of the seven cooling rates, shown in Figure 6.4, is used to initialize the optimization 
problem. 
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The optimal control formulation used in the supervisory control in the case of the (5-1) 
PCE model is given by Eq. 6.7. The initial and final temperatures are fixed at 
60 qinitial CT  and 30 qfinal CT , respectively. The average of the seven cooling rates, 
shown in Figure 6.4, is discretized at the same time points that are used for the 
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discretization during (5-1) PCE model development. Then this discretized average 
cooling profile is used to initialize the optimization problem.  
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The optimal temperature profiles are shown in Figure 6.6. Using both the (1-1) and (5-1) 
models, for faster cooling rates of 15 °C/min and 10 °C/min, the predicted temperature 
profiles to reach the desired dissolution profiles compare well with the actual temperature 
profiles applied to the dosage forms. However for a cooling rate of 1 °C/min, the (5-1) 
model gives a better prediction compared to (1-1) model. The prediction capabilities of 
the models show that the (5-1) PCE model captures the behavior of the system better.  
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Figure 6.6 Optimized temperature profiles using (1-1) and (5-1) PCE models vs. the 
actual temperature profiles 
 
Using discretized temperature profiles also allows the use of optimized temperature 
cycles with variable cooling and/or heating rates. In chapter 5, it is shown that cycling 
temperature profile can be used to reduce the solidification times compared to a slow 
constant cooling rate. Different cycles can be designed to achieve differences in the 
dissolution times. They can be also accommodated in the PCE model to achieve a desired 
dissolution property in shorter time. First, as explained in section 6.3, a PCE model 
would be developed with model input temperature profiles, which correspond to the 
cycling profile. In this case a single input single output (1-1) PCE model cannot be used, 
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since the cycling temperature profiles cannot be represented with a single cooling rate. A 
multiple input single output PCE model, which captures the cycling profile, should be 
developed. This would require a higher number of inputs and thus a higher number of 
data points to build the PCE model. Since the cycling profiles are not monotonic, a higher 
order PCE model could be necessary to capture the experimental data. Next, the model 
would be used in an optimal control framework with a formulation, similar to Eq. 6.7, 
except the constraints on temperatures would allow a cooling and heating cycle.  
 
By using more experimental data points, the PCE based surrogate model can be improved 
to have better model fit and also better prediction. A higher order PCE model can also be 
developed with more data points. Moreover, using a different pharmaceutical formulation, 
which would undergo not only morphological but also crystallinity changes depending on 
the applied control strategies, can result in more diverse dissolution profiles.  
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Figure 6.7 Hierarchical temperature control strategy 
 
A hierarchical control strategy can be implemented on the dropwise additive 
manufacturing process by monitoring the drop size on-line, and selecting a PCE model 
from the PCE model family developed for different drop sizes. One such hierarchical 
control strategy is shown in the flowchart in Figure 6.7. Using the proposed hierarchical 
control strategy, for a measured drop size, the temperature profiles can be optimized to 
reach the desired process outcome, in this case, a desired dissolution profile.  
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6.5 Conclusions 
In this work, a process control strategy for the dropwise additive manufacturing system is 
reported. Using the imaging system, the drop sizes and therefore the dosage amounts are 
monitored. Using the proposed substrate temperature control strategy, the crystallization 
behavior can be tailored and consistent drug morphology can be achieved. A PCE based 
surrogate model is developed to predict the dissolution profile of the solidified drug 
deposition given the temperature profile applied on the substrate. Using this model, a 
hierarchical control system is implemented by monitoring the drop size on-line and 
predicting a temperature profile to achieve the desired dissolution profile for the dosage 
forms created. The process control strategy reported in this chapter is novel not only in 
providing effective control of the drop on demand manufacturing process but also is one 
of the first efforts in the literature demonstrating elements of model-based real time 
release and the concept of quality-by-control, whereby product performance and 
consistent quality are achieved by the design of suitable control strategies. 
 
The reported process control strategy can effectively mitigate variations in the dissolution 
profiles due to variable dosage amounts, hence enabling the application of the DoD 
system for the production of individualized dosage regimens for adaptive clinical trials 
and personalized treatments. The prototype system offers great promise as a tool for 
advancing personalized medicine by allowing the precise production of convenient solid 
oral dosages tailored to the patient on site at hospitals, clinics and even pharmacies. 
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 MODELLING OF CRYSTALLIZATION OF MELT-BASED SOLID CHAPTER 7.
ORAL DRUG FORMS ** 
7.1 Introduction 
Melt-based solid oral drug forms are produced using a dropwise additive manufacturing 
process for pharmaceuticals. In Chapters 3, 5 and 6, both the effects of critical process 
parameters on the quality of the individual dosage forms and the process control 
strategies to control those CPP’s are discussed. It is shown that the crystallization 
temperature affects product solid state characteristics, e.g. morphology and crystal size, 
and thus the dissolution properties and bioavailability of the drug. Therefore the drop 
solidification process following the drop deposition on the substrate should be controlled. 
With this purpose, in Chapter 6 a surrogate model based on polynomial chaos expansion 
was developed to relate the crystallization temperature profile to the final drug property: 
dissolution profile.  
 
This chapter presents a different approach to investigate the solidification and 
crystallization processes of the drug deposits using temperature dependent crystallization 
kinetics and cooling profiles [82]. A model is developed based on the non-isothermal 
                                                 
** This chapter is based on: E. Içten, Z. K. Nagy, and G. V. Reklaitis, “Modelling of 
Crystallization of Solid Oral Drug Forms in a Dropwise Additive Manufacturing System,” 
in 12th International Symposium on Process Systems Engineering and 25th European 
Symposium on Computer Aided Process Engineering, vol. 37, pp. 2195–2200, 2015. 
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Avrami kinetic equation and it incorporates the crystallization kinetics monitored via an 
optical microscopy with a hot stage. This model increases the understanding of 
solidification and crystallization processes from undercooled melts. Using the proposed 
model, the effect of temperature profiles leading to differences in solid-state parameters 
such as the mean size can be investigated.  
 
7.2 Crystallization Model Development 
The solid-state transformation of the melt-based solid oral dosages produced using the 
dropwise additive manufacturing process are modelled based on the modified Avrami 
(1939) kinetic equation [83]. The formulation used for the model development consists of 
15 % drug, naproxen, and 85 % polymer, PEG 3350. The drops are deposited at 60 °C 
and cooled to 20 °C using two different controlled cooling rates, 1 °C/min and 10 °C/min. 
The temperature of the deposited drops is controlled indirectly by controlling the 
temperature of the substrate using a Peltier device placed beneath the substrate on the xy-
stage. The controlled cooling rates are applied through the Labview based automation 
program. This allows control of the rate of solidification of melts and thus control of 
nucleation and crystallization phenomena. Precise control of the drop solidification 
process occurring on the substrate is very important since the crystallization temperature 
profile has a direct effect on product solid-state characteristics. In Chapter 5, it is reported 
that applying a fast cooling rate of 10 °C/min to the deposits containing naproxen results 
in faster dissolution profiles compared to a slow cooling rate of 1 °C/min. Controlling 
crystallization temperature profiles can be used to enhance the solubility of dissolution 
limited drugs such as naproxen. 
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In order to determine the nucleation and growth kinetics experimentally, the solidification 
process under the same conditions are monitored using optical microscopy with a hot 
stage. It is observed that the model formulation undergoes sporadic nucleation and 
spherical crystal growth. Determination of kinetic parameters is described in Section 7.3.  
 
The Avrami equation describes isothermal solid-state transformation reactions based on 
nucleation and growth kinetics, which is widely used for various processes including 
metal, fat and polymer crystallization. The Avrami model equation for different growth 
geometries and types of nucleation is given by Eq. 7.1, where 𝑚𝑠 is total mass of solids 
present in the system at a particular time, 𝑚𝑚𝑎𝑥  is maximum total mass of solid at 
infinity, (𝑚𝑚𝑎𝑥 − 𝑚𝑠) is mass of supercooled material that has not crystallized yet, 𝑡 is 
crystallization time (min), 𝑠 is the geometrical shape factor, 𝐼𝑐 is the number of crystals 
per unit volume in the system (cm-3), 𝐴𝑔 is the area of crystal involved in growth (cm-2).  
 
max( )s s c g
m m m s I At
w     w
 Eq. 7.1 
 
For spherical crystal growth, the geometrical shape factor is 𝑠 = 4𝜋 3⁄  and crystal growth 
𝐴𝑔 is described by Eq. 7.2, where 𝑟 is linear growth rate of crystal radius in time (cm) 
and 𝑔 is growth rate constant for crystals radius per time (cm min-1).  
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For sporadic nucleation, the change in the number of nuclei as a function of time, 𝐼𝑐 is 
described by Eq. 7.3 where 𝑗 is nucleation rate constant (cm-3 s-1). 
 
cI j t   Eq. 7.3 
 
In the dropwise additive manufacturing process, different controlled temperature cooling 
profiles are applied to the deposited drops in order to achieve the targeted dissolution 
behavior. Temperature profiles applied to the drug deposits as a function of time and 
cooling rate are shown in Eq. 7.4, where the induction time is defined as a function of 
cooling rate  𝑡𝑖𝑛𝑑 = 𝑡𝑖𝑛𝑑(𝑟𝑐𝑜𝑜𝑙). 
 
( ) ( )i cool indT t T r t t     Eq. 7.4 
 
In order to capture the effect of temperature on crystallization kinetics the modified 
Avrami equation is used, which is extended for non-isothermal kinetics by using 
temperature dependent nucleation and growth rates [84]. Since the cooling profiles are 
represented as a function of time, the crystallization model can be expressed as in Eq. 7.5, 
where both 𝑗(𝑇) and 𝑔(𝑇) are temperature and therefore time and cooling rate dependent.  
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The growth rate constant is described as 𝑔(𝑇) = 𝛼1 ∙ 𝑇 + 𝛼2. The parameters 𝛼1 and 𝛼2 
are a function of cooling rate which are determined experimentally as described in 
Section 7.3. The nucleation rate constant is described as  𝑗(𝑇) = 𝛽1 ∙ 𝑇 + 𝛽2 . The 
parameters 𝛽1  and 𝛽2  are a function of cooling rate which are also determined 
experimentally as described in Section 7.3. 
 
7.3 Determination of Kinetic Parameters 
The kinetic parameters of the model formulation consisting of 15 % naproxen and 85 % 
PEG 3350 are determined experimentally, based on the crystallization behavior observed 
using an optical microscopy with a hot stage when a particular cooling profile is applied.  
The two cooling rates used in this study are 10 qC/min and 1 qC/min. 
 
7.3.1 Induction Time 
The cooling rates applied to the deposits effect the induction time. Induction times 
corresponding to 10 qC/min and 1 qC/min are determined experimentally as 2.2 min and 
12 min, respectively. In the model development, it is assumed that the changes in the 
induction times are linearly proportional to the change in the cooling rates. 
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Figure 7.1 Nucleation kinetics for different cooling rates 
 
7.3.2 Nucleation Rate 
For a cooling rate, the change in the number of nuclei per volume as a function of time is 
determined from the images captured using optical microscopy at different times during 
the whole cooling duration. For the same cooling rate, the parameters 𝛽1  and 𝛽2  are 
determined by fitting a linear relation to experimental data points. Here, the data fit can 
be improved by excluding the data points after the number of crystals reaches a constant 
value. The nucleation rate parameters determined for the two cooling rates used in the 
experiments are shown in Figure 7.1. Next, these parameters are used to calculate the 
nucleation rate parameters 𝛽1  and 𝛽2  when cooling rates  10 ℃ 𝑚𝑖𝑛⁄ ≥ 𝑟𝑐𝑜𝑜𝑙 ≥
1 ℃ 𝑚𝑖𝑛⁄  are applied to the deposits. Here it is again assumed that the changes in the 
parameters are linearly proportional to the change in the cooling rates. 
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7.3.3 Growth Rate 
For a particular cooling rate, the linear growth rate constants of crystal radius as a 
function of time is determined from the images captured through optical microscopy. The 
calculation of linear growth rate of crystal radius are depicted for fast cooling rate of 1 
qC/min and slow cooling rate of 10 qC/min in Figures 7.2 and 7.3.  
 
  
  
Figure 7.2 Optical microscopy images used for growth rate estimation with cooling rate 
1°C/min 
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Figure 7.3 Optical microscopy images used for growth rate estimation with cooling rate 
10°C/min 
 
White arrows represent the dynamic changes in the linear growth rate of crystal radius in 
consecutive images, when either of the cooling rates is applied to the deposits. By 
measuring the changes in the growth front throughout different cooling profiles, the 
dynamic growth rate constants parameters 𝛼1 and 𝛼2 are determined. The growth rates 
determined for the two cooling rates used in the experiments are shown in Figure 7.4. 
These parameters are used to calculate the growth parameters 𝛼1 and 𝛼2 when cooling 
rates  10 ℃ 𝑚𝑖𝑛⁄ ≥ 𝑟𝑐𝑜𝑜𝑙 ≥ 1 ℃ 𝑚𝑖𝑛⁄  are applied to the deposits. Here, it is again 
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assumed that the changes in the crystallization parameters are linearly proportional to the 
change in the cooling rates. 
 
 
Figure 7.4 Growth kinetics for different cooling rates 
 
7.4 Crystallization Modelling Results and Discussion 
Using the modified Avrami model, the solid fraction of the dosage forms produced of the 
model melt-based formulation by the dropwise additive manufacturing process with 
different cooling rates is calculated as a function of time. The differential equation, Eq.5, 
is solved numerically. The time and cooling rate dependence of kinetic parameters are 
taken into account as explained in Section 7.2. The nucleation and growth kinetic 
parameters presented in Section 7.3 are used in the model. The solidification rates of the 
dosage forms solidified with cooling rates of 1 qC/min and 10 qC/min is shown in Figure 
7.5. For both cooling rates, the experimentally determined and calculated times to reach 
100% solidification are compared in Table 7.1.  
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Figure 7.5 Solid percentages of the dosage forms using the developed crystallization 
model 
 
Table 7.1 Calculated and experimental solidification times under different cooling rates 
Cooling Rate 1 °C/min 10 °C/min 
Experimental Solidification Time  5 min 1.1 min 
Calculated Solidification Time 7 min 0.8 min 
 
For 10 qC/min, complete solidification occurs after 1.1 min, whereas in experiments this 
time was observed as 0.8 min. For 1 qC/min, complete solidification occurs after 5 min, 
whereas in experiments this time was 7 min. The mismatch between the experimentally 
observed and modeled solidification times could potentially be reduced by using 
experimental data points corresponding to intermediate cooling rates and checking the 
validity of the linearity assumptions made during the kinetic parameter estimation. The 
kinetic parameters can be estimated more accurately through monitoring a larger area. 
This would allow both detecting more nucleation points and detecting growth rates more 
accurately through monitoring the complete area of spherical crystals. 
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The developed model is used to determine the mean size of crystals when different 
cooling rates are applied. For different cooling rates, the time, t*, to reach 100 % 
solidification is calculated. The number of nuclei formed per image area at t* is 
calculated and mean crystal radius is calculated, which are plotted in Figure 7.6 for 
cooling rates from 1 to 10 qC/min. By increasing the cooling rate from 1 to 10 qC/min, 
the mean size is decreased from 434 to 307 Pm, which is in accordance with the increase 
in the dissolution rate observed in Chapter 5 when fast cooling rate of 10 qC/min is 
applied to the same model formulation containing 15 % naproxen and 85 % PEG 3350. 
According to model results, the minimum radius of 217 Pm can be achieved with a 
cooling rate of 5.5 qC/min. This can be used to further increase the dissolution rate of 
naproxen for which dissolution is limiting. 
 
 
Figure 7.6 Crystallization model results for mean crystal radius vs cooling rate 
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7.5 Conclusions 
In this chapter, a crystallization model based on non-isothermal Avrami kinetic equation 
is presented. The model is developed for the cooling temperature dependent solid-state 
transformation of the melt-based solid oral dosages produced using the dropwise additive 
manufacturing process. The kinetic parameters of the model formulation are determined 
experimentally, based on the crystallization behavior observed using an optical 
microscopy with a hot stage when either a fast or slow cooling profile is applied. For 
induction time, nucleation and growth kinetics, it is assumed that the changes in the 
crystallization parameters are linearly proportional to the change in the cooling rates for 
intermediate cooling rates. 
 
The model is used to calculate the solidification times of the dosage forms and their mean 
crystal sizes under two different cooling profiles. The experimentally observed and 
modeled solidification times have the same trend. The accuracy of the model can be 
improved by using experimental data points corresponding to intermediate cooling rates 
and by validating the linearity assumptions made during the kinetic parameter estimation.  
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 AMORPHOUS AND SELF-EMULSIFYING MELT-BASED SOLID CHAPTER 8.
ORAL DOSAGE FORMS 
8.1 Introduction 
Although oral drug delivery is the major route for the administration of many drugs, 
increasing the oral bioavailability of most compounds is still a challenge. It has been 
suggested that more than 40% of new chemical entities (NCE) have low aqueous 
solubility, which leads to poor oral bioavailability, high intra- and inter-subject variability 
and lack of dose proportionality [85], [86]. In recent years, several delivery methods are 
being investigated to eliminate these disadvantages. These methods include use of 
solution or emulsion based formulations, nanocrystals, solid dispersions, amorphous 
formulations and lipid based formulations among others [33], [85]–[87].  It is 
demonstrated that via the DAMPP process, bioavailability of poorly water soluble drugs 
can be enhanced by using solvent-based amorphous or crystalline formulations [18] and 
melt-based crystalline formulations [19].  
 
The main goal of this study is to developing alternative dosage forms to increase the 
bioavailability of poorly water soluble drugs that can be used in the DoD manufacturing 
system. Therefore both amorphous and lipid-based formulations are investigated. Lipids 
with low-melting temperatures can be used in the DAMPP process developed for melts-
based formulations.  
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8.1.1 Amorphous Drug Formulations 
The solubility of active ingredients can be increased by formulating the drug in the 
amorphous form. The drawback of amorphous drug formulations is their high instability. 
In comparison to amorphous forms, crystalline forms have lower energy states and are 
thermodynamically favored. Although stability is a critical issue in amorphous drug 
formulation, in some cases it can be overcome with the use of polymer additives that 
inhibit crystallization [33] or with a process control strategy that slows down or prevents 
crystallization of the compound. Performing a thorough stability analysis is common 
practice to assure that the final drug product contains the desired API form during the 
shelf-life of the products. On-demand production systems, such as DAMPP, have a great 
advantage for the manufacturing of amorphous drug products, because the dosage forms 
is produced following the prescription of the medicine by the physician and consumed 
within the prescription time. Thus, using DAMPP process, the long-term shelf-life 
constraints would be eliminated. 
 
8.1.2 Self-Emulsifying Drug Delivery Systems 
The solubility of poorly water soluble and highly lipophilic drugs can be increased using 
lipid-based formulations, which can be achieved by incorporating the drug into inert lipid 
vehicles such as oils, surfactants, emulsions and self-emulsifying drug delivery systems 
(SEDDS) [87], [88]. SEDDS are defined as isotropic mixtures of oils, solid or liquid 
surfactants, or alternatively, one or more hydrophilic solvents and co-solvents/surfactants 
[87]. The most frequently used excipients for lipid based formulations are reported as 
dietary oils and various pharmaceutically-acceptable surfactants [86]. Self-emulsifying 
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drug delivery systems form oil in water (o/w) emulsions upon dilution and mild agitation 
in aqueous environment. After the drug products enter the GI track, emulsion is achieved 
by chemical rather than mechanical means. This makes SEDDS easy to manufacture and 
stabilize compared to emulsions. Consequently, for lipophilic drug compounds displaying 
dissolution rate-limited absorption, SEDDS systems can improve the rate and extent of 
absorption and result in more reproducible blood time profiles [87]. 
 
8.2 Investigation of Amorphous and Self-Emulsifying Drug Delivery Systems for 
DAMPP 
The two aims of this study are creating an amorphous drug product and also investigating 
self-emulsifying drug delivery systems. For this purpose, celecoxib is chosen as the 
model API which exhibits lipophilic properties and low solubility in aqueous 
environment. Several lipids and surfactants are investigated for the use with the DAMPP 
process. While selecting the lipid and surfactants used in the formulations, material 
properties that affect the printability of the formulations, such as the melting temperature 
and viscosity, are taken into account.  
 
The excipients that are investigated for the use in the DAMPP process are shown in Table 
8.1. All materials are provided by Gattefosse (Paramus, New Jersey).  The main reason 
for selecting these excipients was their relatively low melting points. The current 
DAMPP prototype system is best suitable for formulations with melting temperatures of 
less than 70 °C, which can be increased by suitable design of the temperature control 
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system. For increased operating temperatures, assuring stability of the API would present 
another limitation on formulation selection.  
 
Table 8.1 Lipid-based excipients used in DAMPP system and their properties  
Excipient Type Physical Form 
Average Melting 
Temperature 
Solubility / 
HLB 
Compritol 
888ATO 
Lipid Powder 70 °C 
Insoluble in 
water 
Precirol ATO 5 Lipid Powder 56 °C 
Insoluble in 
water / 2 
Gelucire 44/14 Surfactant 
Semi solid 
block 
44 °C 14 
Labrasol Surfactant Liquid undetermined 12 
 
In addition to material rheological properties, chemical properties of the excipients also 
play an important role in the final drug product since their nature and amount determine 
the overall quality of the emulsions obtained. Non-ionic surfactants with relatively high 
hydrophilic-lipophilic balance (HLB) are recommended to be used with or without lipid 
excipients to promote self-emulsification or micro emulsification. Due to their relatively 
low toxicity, the acceptable quantities are limited primarily by their physical stability in 
the final dosage form [86]. HLB reflects the proportion of water soluble to lipid soluble 
moieties in each material. The classification of surfactant function based on their HLB 
values is shown in Figure 8.1.  
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Figure 8.1 Hydrophilic – Lipophilic Balance (HLB) scale [89] 
 
For initial formulation study, a US patent for solid solution beadlet (US 6,692,767) is 
followed [90]. For a self-emulsifying formulation, lipid and surfactant amounts are 
suggested to have between 20 to 97% and 3 to 40% by weight, respectively.  
 
a. The first formulation consists of 60% compritol, 30% labrasol and 10% 
celecoxib. In the DAMPP process, the temperatures of the reservoir, tubing and 
pump temperature controllers are set at 90 °C, 95 °C and 157 °F, respectively. 
Although the operating temperature is increased to the highest operating limit, this 
didn’t prevent the formulation from solidifying within the tubing. Due to its high 
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melting temperature, compritol is found not suitable for the use in the current 
prototype DAMPP system. Also, high hydrophobicity of the formulation creates a 
problem while cleaning the processing line. Cleaning solutions, including soap, 
soap-water and ethanol, could not be pumped through the processing line after 
running this formulation. Compritol is soluble in chloroform and methylene 
chloride under heating conditions, but these solvents are avoided for use with 
DAMPP due to safety concerns. 
b. Second formulation consists of 60% precirol, 30% labrasol and 10% celecoxib. 
This formulation was printed successfully with the DAMPP process and the 
reproducibility of the drops was within the desired 5% range. The temperatures of 
the reservoir, tubing and pump temperature controllers were set at 90 °C, 95 °C 
and 157 °F, respectively. However, cleaning the system after operation was a 
challenging task because the formulation is very hydrophobic. The processing line 
could not be cleaned with cleaning solutions, including soap-water and ethanol, 
after running this formulation. Therefore tubes should be replaced after each 
operation. This is also an indicator of the poor solubility of the formulation in 
aqueous media. When tested for the dissolution behavior, the dosage forms 
consisting of this formulation neither dissolved nor formed an emulsion in water 
within the first 30 minutes. Potentially, this formulation could be used for a 
sustained release formulation. For such applications, chloroform and methylene 
chloride could be used to clean the system under a fume hood.  
c. Third formulation consists of 90% gelucire 44/14 and 10% celecoxib. After 
unsuccessful formulations of SEDDS, lipids were eliminated from the formulation 
148 
 
 
148 
and replaced with a solid surfactant. Since gelucire has a melting temperature of 
44 °C, the DAMPP process can be run at lower temperatures than the maximum 
allowable temperatures. The temperatures of the reservoir, tubing and pump 
temperature controllers were set at 70 °C, 90 °C and 140 °F, respectively. This 
formulation is used to produce dosage forms, which contain amorphous form of 
celecoxib and yield self-emulsification. The detailed analysis of dosage forms is 
presented in the following section. 
 
8.3 Materials and Methods 
8.3.1 Materials and Formulation 
In this study, celecoxib (CEL) is chosen as the model API to form melt formulations with 
the surfactant, gelucire 44/14 (Lauroyl macrogol-32 glycerides EP). Celecoxib is 
purchased from ChemShuttle (Union City, California). Gelucire 44/14 is provided by 
Gattefosse (Paramus, New Jersey). Celecoxib and gelucire 44/14 are mixed in (10:90) 
weight ratio. The mixture is comelted at 70 °C until completely melted. The melt 
formulation is printed both on inert tablets and on polymeric films prepared with 
hydroxypropyl methylcellulose (HPMC) (E50). Inert tablets are provided by 
GlaxoSmithKline (Collegeville, Pennsylvania). HPMC (E50) is purchased from Sigma 
Aldrich Corporation (St. Louis, Missouri). 
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8.3.1.1 Film Preparation 
In order to make a 5% (w/v) polymer solution, 1 gr HPMC powder (E50) are dissolved in 
20 ml water at 90 °C. The 5% (w/v) HPMC solution is stirred at room temperature 
overnight to ensure that the polymeric chains were homogeneously dispersed in the 
solution and cast onto a Petri glass. After drying is completed, the film is peeled off. 
 
8.3.2 Methodology 
After deposition of the drops onto the film, the resulting dosage forms were analyzed for 
solid-state characteristics, self-emulsifying behavior of the formulation and dissolution 
behavior of the API. The dosage forms were created and analyzed at the same time and 
thus varying ambient conditions, such as relative humidity, were not impactful on the 
results. 
 
8.3.2.1 Reproducibility of Dosage Amounts 
In this study, dosage forms are produced with target dosage of 1.5 mg of API. A single 
dose corresponds to one drop containing dosage form. The drop size can be altered by 
changing the pump and printing operating parameters such as nozzle diameter, 
displacement, volume strokes and rate. In addition, by changing the number of drops in a 
single dose, one can increase the dosage amount. The reproducibility is analyzed both 
gravimetrically and through image analysis. To analyze reproducibility gravimetrically, 
substrates are weighed on an Omega AL-201s balance. Next, a specific number of drops 
(in this study one drop) are deposited on the substrate to reach the target dosage amount. 
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The dosage forms are then subjected to room temperature until the deposits solidify. 
After solidification of the drops, the substrates are weighed again to determine the total 
mass of the deposits on the film. The amount of drug is determined by multiplying this 
mass of solids by the composition of drug in the solution (10 %). These results are then 
used to analyze how consistently and accurately the dosage forms are created. 
 
8.3.2.2 Raman Microscopy 
A Thermo Scientific DRX Raman Microscope equipped with a 532 nm laser is used to 
analyze the crystal morphology of the melt formulations. First, the spectra of pure 
crystalline celecoxib and gelucire 44/14 solid dispersion are obtained. Pure celecoxib and 
pure gelucire 44/14 are analyzed to obtain the spectra of pure compounds. The spectra of 
the melt formulation consisting of 10% celecoxib and 90% gelucire 44/14 are obtained by 
analyzing the drops of the melt formulation deposited using the dropwise additive 
manufacturing process. 
 
8.3.2.3 X-ray Diffraction 
X-ray analysis was performed to ascertain the form of the drug in the formulation. The 
samples were analyzed using a Rigaku Smartlab diffractometer (The Woodlands, Texas) 
with CuKα radiation source and a D/tex ultra-detector. The voltage and current were 
40kV and 44mA respectively and the range of data collection was from 5 to 40° 2θ at 
scan speed of 10°/min and a step size of 0.04°. 
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8.3.2.4 Nanoparticle Tracking Analysis 
NTA was utilized to characterize the solution formed after dissolving the SEDDS 
formulation containing 1mg of celecoxib in 160 mL of distilled water. The emulsion that 
was formed after dissolution of the dosage form was analyzed using the Nanosight LM10 
(Malvern instruments, Massachusetts) instrument. The light source of the instrument was 
a green laser of 532 nm wavelength. The light scattered through the particles was 
visualized using a 20X magnification objective which was attached to a CMOS camera. 
Particle size distribution analysis was performed by acquiring a 30 sec video and 
processing it using the Nanosight NTA 3.0 software. 
 
8.3.2.5 Dissolution Testing and High Performance Liquid Chromatography Analysis  
Dissolution testing of crystalline CEL and the SEDDS formulation was performed in 900 
mL of pH 6.8 10mM phosphate buffer in USP-I paddle dissolution apparatus. 
Experiments were performed at 100 rpm at 37°C. Aliquots were taken from the 
dissolution vessels and filtered through 1µ glass filter. The volume of the sampled 
aliquots was replenished using fresh dissolution medium. The filtered samples were then 
analyzed using Agilent 1100 series HPLC (Santa Clara, California) fitted with a UV 
detector. Samples were run through a Kinetex 2.6 µ C18 column (150 x 3.0 mm) at a flow 
rate of 0.5 mL and column temperature of 50°C. The mobile phase consisted of 30% pH 
3.5 water adjusted using phosphoric acid and 70% methanol. The injection volume was 
20µL and the absorbance was monitored at the wavelength of 250 nm. Each experiment 
was performed in three replicates. 
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8.4 Results and Discussion 
The production of SEDDS is demonstrated with the DAMPP system. The melt-based 
SEDDS formulation consists of 10% celecoxib and 90% gelucire 44/14 by weight. 
Celecoxib is a lipophilic and poorly water soluble drug. Gelucire 44/14 is a non-ionic 
surfactant with a relatively high hydrophilic−lipophilic balance (HLB) of 14. The 
formulation is comelted at 70 °C and the temperature of the process is controlled at 70 °C 
during printing. The residence time is less than 5 min.  
 
8.4.1 Reproducibility of Dosage Forms 
Using the DAMPP system, dosage forms are produced using the nozzle with internal 
diameter of 17 AWG, pump displacement of 2.5, pump volume stroke of 1 and pump rate 
of 500. The reproducibility of the dosage forms produced is shown in Table 8.2. The 
relative standard deviation (RSD) is less than 2%. These RSD values are well within the 
5% RSD limit required by the FDA. The images of the dosages used in the dissolution 
testing is shown in Figure 8.2. The images are recorded via the online imaging system, 
after the drops are ejected through the nozzle. 
 
Table 8.2 Reproducibility of SEDDS  
Formulation 
Number of drops 
printed 
Average dosage 
amount (mg) 
RSD (%) 
10% celecoxib    
90% gelucire 44/14 
1 1.571 1.572 % 
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Figure 8.2 Online drop images 
 
8.4.2 Solid-State Analysis 
The crystal morphology of the dosage forms are analyzed with a Raman microscopy. 
Raman spectra of melt-based drug deposits of 90% gelucire and 10% celecoxib, pure 
gelucire and pure crystalline celecoxib are presented in Figure 8.3. The grey bands are 
used to clearly show the differences in the peaks of crystalline drug and drug peaks found 
in the dosage forms. These differences in the peak position, intensity and width are 
compared with reference spectra of amorphous and crystalline celecoxib from the 
literature and it is concluded that the celecoxib found in the dosage forms is in 
amorphous form [91], [92]. The crystalline and amorphous spectra of celecoxib are 
presented in Figure 8.4, which is modified from Andrews, et al. (2010) [91]. 
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Figure 8.3 Raman spectras of SEDDS formulation, pure gelucire 44/14 and pure 
crystalline celecoxib 
 
In Figure 8.3., the crystalline spectrum has a double peak at 1614 cm-1 with a slight 
shoulder at 1599cm-1, whereas the spectrum of the dosage form has a double peak with 
distinct maximum points at 1616cm-1 and 1597 cm-1. Likewise, the spectrum of the 
dosage form contains a double peak with distinct maximum points at 1185 and 1200 cm-
1 whereas the spectrum of crystalline celecoxib contains a double peak with a maximum 
point at 1192 cm-1 and a shoulder at 1201 cm-1. 
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Figure 8.4 Raman spectras of amorphous and crystalline celecoxib. Modified from 
Andrews, et al. (2010) [91]. 
 
The crystallinity of the dosage forms are further analyzed with X-ray diffraction. The 
XRD spectra of melt-based drug deposits of SEDDS formulation with 90% gelucire and 
10% celecoxib, pure gelucire and pure crystalline celecoxib are presented in Figure 8.5. 
Crystalline peaks of celecoxib were not observed in the dosage forms produced with the 
SEDDS formulation. Along with the Raman analysis, the presence of amorphous 
celecoxib in the dosage forms is proven. 
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Figure 8.5 XRD spectra of crystalline celecoxib, pure gelucire 44/14 and SEDDS 
Formulation with 10% celecoxib and 90% gelucire 44/14 
 
8.4.3 Analysis of the Self-Emulsifying Drug Delivery System 
The formulation displays spontaneous self-emulsifying characteristics upon dilution in 
aqueous media. In order to further analyze the resulting emulsion, a technique called 
nanoparticle tracking analysis (NTA) is used. NTA utilizes the properties of both light 
scattering and Brownian motion in order to obtain the particle size distribution of 
nanoparticles in solution [93]. The size distribution profile of emulsion droplets obtained 
from the SEDDS containing of 10% celecoxib and 90% gelucire is presented in Figure 
8.6. NTA also enables visualization and recording of particles. Figure 8.6 also displays a 
157 
 
 
157 
particle image that is obtained during NTA analysis. White dots correspond to the 
particles observed in contrast to the black background. Using the software, the mean 
particle size is found as 160.76 nm. Thus, the celecoxib-gelucire (10:90) formulation 
results in a submicron spontaneous emulsion.  
 
 
Figure 8.6 Size distribution profiles and particle images for SEDDSs. 
 
8.4.4 Dissolution Testing 
Dissolution testing was performed on the dosage forms manufactured of the self-
emulsifying formulation. In Figure 8.7, the dissolution profiles of the dosage forms are 
compared with the crystalline celecoxib. The crystalline solubility limit of celecoxib has 
been reported in a range of 1.1 to 1.5 µg/ml [94], [95]. The solubility limits are shown as 
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the dotted black lines, which correspond to a release of 63-85% of the SEDDS dosage 
forms. The solubility between two limits are shown with the grey band in the figure. For 
the SEDDS, the dissolution of 70% is reached in 10mins. The dissolution reaches a 
plateau at around 75% dissolution which indicates that the crystalline solubility limit is 
reached and increasing the testing time does not affect the release profile. On the other 
hand, the crystalline celecoxib reaches only 22% in 2 hours under the same conditions. 
Thus, the SEDDS formulation promotes rapid dissolution and enhances the solubility of 
celecoxib. 
 
Although celecoxib in the SEDDS is in amorphous form; during dissolution testing it 
does not exceed crystalline solubility and present amorphous solubility. This can be due 
to rapid crystallization of celecoxib when dissolved in the buffer solution. Celecoxib is a 
rapid crystallizer and its crystallization is shown to be inhibited in the presence of 
polymers [33], [92]. However, the effect of gelucire 44/14 on the crystallization of 
celecoxib in solution is not known. 
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Figure 8.7 Dissolution of celecoxib found in SEEDS formulation and crystalline 
celecoxib 
 
8.5 Conclusions 
The dropwise additive manufacturing process is suitable for the production of various 
melt-based dosage forms. This temperature controlled process enables the production of 
lipid-based dosage forms, reproducibly and consistently. In this chapter, the use of 
DAMPP process for the production of alternative drug formulations such as self-
emulsifying drug delivery systems and amorphous dosage forms is investigated. For this 
purpose, various lipid based excipients are investigated for the use in the DAMPP process. 
A melt-based formulation consisting of celecoxib and gelucire (10:90) is developed 
which forms a submicron spontaneous emulsion system upon contact with water. Another 
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advantage of this formulation is that the celecoxib is present in its amorphous form. This 
formulation appears to lead to enhancement of the solubility of celecoxib.  
 
The DAMPP process is a viable method for on-demand production of amorphous and 
self-emulsifying dosage forms. The on-demand production of amorphous dosage form 
not only solves the solubility issues of the active ingredient but it also reduces concerns 
with the shelf-life duration in which the active should remain in stable in the amorphous 
form.  
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 FUTURE DIRECTIONS CHAPTER 9.
The flexibility in adjusting dosage amount makes DAMPP attractive as a mini-
manufacturing platform for producing dosages for early clinical trials. As a tool for 
clinics, hospitals or compounding pharmacies, DAMPP could produce individualized 
doses of drugs with high inter-patient therapeutic variability. This chapter presents 
studies that could be used to further advance dropwise additive manufacturing of 
pharmaceutical products and lead to commercialization of this technology.  
 
Current proto-type DAMPP process is a viable system that can successfully process 
various solvent- or melt-based formulations. Automation, monitoring and control systems 
enable control of important process parameters and assure critical quality attributes. 
Future directions include advancing the manufacturing process, increasing process 
monitoring and thus process control capabilities and also investigating new product forms. 
 
9.1 Process 
The future user of the system is envisioned to be a health professional, who is not 
required to have a technical background. Therefore, a new version of the proto-type 
system, DAMPP V2.0, should be developed, which is compact and easy to transport to  
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medical facilities and easy to operate. As a part of our current commercialization efforts, 
Dr. Arun Giridhar is working on designing a new version of the DAMPP process.  
 
Here are some recommendations to advance the dropwise additive manufacturing process 
and simplify process operation, which can immediately be taken into account for 
DAMPP V2.0: 
 
x All process parameters need to be controlled through the automation program 
rather than manually. Currently there are some parameters, including pump 
temperature set point and pump displacement that cannot be changed through the 
automation program.  
x Modification of the process units, such as changing the tubes or the nozzle, needs 
to be relatively easy. The tubing needs to be changed between different 
formulations to prevent cross-contamination. The nozzle needs to be changed 
between manufacturing of different doses. In the current system, either change 
requires dismantling the whole tubing-nozzle connections and usage of various 
tools, such as allen keys and flushnut wrench. Eliminating the tubing and 
connecting the nozzle directly to the pump discharge would significantly simplify 
process operation, especially for health professionals.  
x The current system can be used for melt-based formulations with a melting point 
up to 70 °C and solidification within the tubing is observed for higher melting 
temperature formulations. Shortening the processing line would prevent 
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solidification within the tubing also for formulations with high melting points and 
expand the operating temperature region.  
x The limiting factor for the operating temperature is the maximum operating 
temperature of the pump. By investing in a pump that has a wider operating range, 
the product range can be increased. 
x The limiting factor for the operating speed of the system is the staging speed. A 
fast operating staging can be used to further increase the operating rate. 
Alternatively, the pump can be attached to a moving stage and the substrate can 
be stationary.  
x A compact controller design that will contain all the controllers, i.e. pump, staging 
and multiple temperature controllers, will significantly reduce the size of the 
proto-type system and can be an important first step towards a portable design. 
 
9.2 Process Monitoring and Control 
Future additions to the DAMPP real time process management system include addition of 
on-line spectroscopic monitoring of the final dosage form in order to further ensure 
quality of the final product. Online spectroscopy, preferably Raman, can be used to 
control the solid state of the products by manipulating the temperature profile in closed-
loop. One limitation of a spectroscopy is that the equipment needs to be compact and fit 
to the mini-manufacturing system. Preliminary studies with a portable Raman 
spectrometer (Wasatch Photonics, Utah) with size (12.7 x 16.5 x 5.1 cm) showed that the 
equipment can be attached to the DAMPP process and Raman spectra can be collected 
using the probe. Thus it can be used to control the crystallinity (or morphology) of the 
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dosages. For spectroscopic techniques, homogeneity of the deposits is crucial. Previously, 
NIR spectroscopy could not be used on solvent-based deposits that present coffee ring 
effect upon evaporation of the solvent. On the other hand, melt-based deposits are shown 
to be well distributed and are successfully analyzed with a spectroscopic technique. 
 
Currently, IR camera can be used to monitor the spatial distribution of melt deposit 
temperature. However it is not used as a feedback to the temperature controller. 
Combined with the online spectroscopy, online IR measurement would allow precisely 
controlling the drug morphology real time. This would enable achieving a desired 
morphology regardless of the drop size and also eliminate offline solid-state 
characterization. 
 
Additional cameras can be added to the system to monitor the drop formation and/or 
deposition. Currently, camera monitors the primary drop and any satellite drops formed 
close the primary drop. By placing another camera to monitor drop break up from the 
nozzle, the satellite drop formation can be monitored more accurately using the arbitrary 
rotational symmetric shape model. Another camera can be used to monitor the drop 
deposition on the substrates via stain detection. In the case of drop deposition, a drop 
would show up as a contrasting material on the substrate by increasing the average pixel 
value of the image. The stain detection can be implemented in the Labview automation 
program where the pixel values of an array can be used to detect a presence of 
abnormality. Stain detection could be useful to detect when a drop does not fall even 
though it is triggered, or when a drop falls without being triggered, or if satellite drop 
165 
 
 
165 
generation or splashing would occur. Using the Labview program, the operator can be 
warned of the possible reasons of the fault. 
 
9.3 Products 
DAMPP process is used to demonstrate printing solvent-based and melt-based 
formulations on a variety of substrates, including polymeric films and placebo tablet. In 
the future, the product range can be increased by investigating other formulations such as 
suspensions, which would allow producing both low and high-drug loading dosage forms. 
Printability of new formulations should be investigated to use them in DAMPP. As 
shown in previous chapters, DAMPP has its limitations on the selection of formulations. 
Material rheological properties, e.g., surface tension, viscosity, operating temperature and 
solubility of the formulations can represent challenges while printing and also while 
cleaning the system after printing. 
 
Also use of other substrates, such as capsules or tablets with multiple wells, should be 
investigated. Printing into capsules would eliminate potential peeling of deposits off the 
substrate. Since increasing number of treatments involve a cocktail of different drugs, 
combination products is a promising application. Printing on tablets with multiple wells 
would allow manufacturing of combination products, where multiple formulations do not 
contact each other thus preventing drug interactions. Another way to manufacture 
combination products is creating multiple layer dosage forms, where the drug interactions 
can be prevented through applying an inert coating layer in between. Applying a coating 
layer could also be used for taste-masking purposes or for sustained release formulations. 
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In addition to small molecule drug products, DAMPP could also be used to produce 
sterile drug products for large molecule drugs in large scale. Since sterility is an 
important concern, small scale manufacturing of the sterile products might not be feasible. 
However the disposable nature of the tubing used as processing line would simplify 
sterilization of the system. 
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Appendix A LabVIEW Flowsheets 
The automation program described in Chapter 3 is developed in NI LabVIEW 
environment. The LabVIEW flowsheets are presented in Appendix A.  
 
First, all of the input parameters are read from the Intermediate Input File generated 
via the Knowledge Provenance Management System, as shown in Figure A.1. 
 
 
 
 
 
178 
 
 
 
Figure A.1 Reading the input information from the Intermediate file generated by KProMS 
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For processing melt-based formulations, the temperature control is used. Next, the 
code connects to all the temperature controllers first through visa ports, as shown in 
Figure A.2.  
 
 
Figure A.2 Connecting to temperature controller visa ports 
 
The substrate temperature controller is set as shown in Figures A.3 through A.10. 
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180 
 
Figure A.3 Setting the substrate temperature controller to heating mode 
 
 
Figure A.4 Turning the substrate temperature controller on 
 
 
Figure A.5 Setting the substrate temperature controller high operating temperature to 
60 °C 
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Figure A.6 Setting the substrate temperature controller low operating temperature to 
0 °C 
 
 
Figure A.7 Turning the substrate temperature controller alarm on 
 
 
Figure A.8 Setting the setpoint temperature for substrate temperature controller 
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Figure A.9 Setting the substrate temperature controller high alarm 20 °C above the 
setpoint temperature 
 
 
Figure A.10 Setting the substrate temperature controller low alarm at 0 °C 
 
The reservoir temperature controller is set as shown in Figures A.11 through A.14. 
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Figure A.11 Turning the reservoir temperature controller on 
 
 
Figure A.12 Setting the reservoir temperature controller setpoint temperature 
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Figure A.13 Setting the reservoir temperature controller alarm low to 10°C lower than 
setpoint 
 
 
Figure A.14 Setting the reservoir temperature controller alarm high to 10°C higher 
than setpoint 
 
The tubing temperature controller is set as shown in Figures A.15 through A.18. 
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Figure A.15 Turning the tubing temperature controller on 
 
 
Figure A.16 Setting the tubing temperature controller setpoint temperature 
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Figure A.17 Setting the tubing temperature controller alarm low to 10°C lower than 
setpoint 
 
 
Figure A.18 Setting the tubing temperature controller alarm high to 10°C higher than 
setpoint 
 
Next, the temperature range is checked before drop deposition starts. If the 
temperature is not within +/- 3°C within the temperature controller setpoints, drop 
deposition will not start. The logic is shown in Figures A.19 to A 20. 
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Figure A.19 Checking temperature range for reservoir and tubing controllers 
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Figure A.20 Checking temperature range for substrate temperature controllers 
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The next step is initiating the drop deposition process, as shown in Figure A.21. Here, 
the printing settings are pulled up from the input file; the output file is generated; and 
it is connected to the pump and staging controllers. If the process is used without 
temperature control, then the code by passes the previous steps and directly starts 
with the drop deposition.   
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Figure A.21 Generating the output file, pulling up printing settings and connecting to 
pump and staging controllers 
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The staging motors are turned on and pump is set to run forward, as shown in Figures 
A.22 to A.24. 
 
 
Figure A.22 Turn staging motor for x-direction on 
 
 
Figure A.23 Turn staging motor for y-direction on 
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Figure A.24 Setting pump to move in forward direction 
 
The staging is moved to home position in x and y directions, as shown in Figures 
A.25 to A.26. 
 
 
Figure A.25 Moving staging to home position in x-direction 
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Figure A.26 Moving staging to home position in y-direction 
 
Next, the logic loops allow for the boustrophedon movement to be executed, as 
shown in Figure A.27. The staging moves in +x direction for even rows and moves in 
–x direction for odd rows. 
 
 
Figure A.27 Logic loops for boustrophedon stage movement 
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Drop deposition is shown in Figure A.28. After each deposition, the x and y location 
of the drop are saved as shown in Figures A.29 and A.30. 
 
 
Figure A.28 Depositing drop 
 
 
Figure A.29 Saving x-position on stage 
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Figure A.30 Saving y-position on stage 
 
The case structure allows continuing printing in the same row and moving to the next 
row, as shown in Figures A.31 and A.32. 
 
 
Figure A.31 True: Continue printing in the same row 
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Figure A.32 False: Move to next row y 
 
If temperature controllers are on, record the temperature values as shown in Figure 
A.33. If temperature control is not used, record default values indicating no 
temperature control is used, as shown in Figure A.34. 
 
 
Figure A.33 Read and record temperatures of tubing, reservoir and substrate and 
substrate power output 
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Figure A.34 Record output values for no temperature control 
 
 
Figure A.35 Saving positions and temperatures to file 
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In parallel to drop deposition, the camera is operating. The connection to the camera 
is established as shown in Figure A.36. Acamera.csv file is generated to save drop 
image related calculations. 
 
Figure A.36 Connect to camera 
 
The camera code and the image processing is shown in Figure A.37. 
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Figure A.37  Image processing code 
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The csv files containing the drop deposition and camera calculations are merged and 
saved to the defined output file path, as shown in Figure A.38. 
 
 
Figure A.38 Merge drop deposition and camera files to the output file 
 
The program stops after drop cycle is executed, as shown in Figure A.39. 
 
 
Figure A.39 Stop program after drop cycle is finished 
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After the drop cycle is executed, the user can design a cooling profile using the 
substrate cooling temperature as described in Chapters 5 and 6. For that purpose, 
another LabVIEW program is developed. The user interface of the program is shown 
in Figures 3.8 and 3.9. The program first connects to the substrate temperature 
controller via Visa connection, as shown in Figure A.40. The visa connection to 
substrate temperature controller is shown in Figure A.2 as well. However, at this step, 
also a spreadsheet is generated to save the data in a user defined location. Real time, 
setpoint temperature, read temperature and power output are recorded. 
 
Setting the parameters to the substrate controller are shown in Figures A.3 to A.10. 
These steps are also followed in the substrate temperature control program to setup 
the controller. Next, the designed temperature profiles are implemented in the 
substrate temperature controller, as shown in Figure A.41.  
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Figure A.40 Connecting to the substrate temperature controller and generating output 
file 
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Figure A.41 Executing designed temperature profiles via substrate temperature control program and saving the time series data 
 
204 
 
 
204 
Appendix B MATLAB Codes 
In this section, the MATLAB codes are presented, which are used for PCE surrogate 
modelling in Chapter 6. The model for single input single output case is shown below as 
a representative case. 
 
clear all 
close all 
clc 
  
% Y1 to Y2 dissolution profile time const  (min) 
% U1 to U2 cooling temperature profile (^oC) or (^oC/min) 
  
% %60% dissoln time 
%  
% 5 Input 1 Output 
% U1= [60 30 30 30 30]; 
% Y1=[8]; 
% U2=[60 40 30 30 30]; 
% Y2=[8.8]; 
% U3=[60 54 30 30 30]; 
% Y3=[9.6]; 
% U4=[60 57 45 30 30]; 
% Y4=[10.2];  
% U5=[60 58 50 30 30]; 
% Y5=[10.7]; 
% U6=[60 58.5 52.5 37.5 30]; 
% Y6=[11.5]; 
% U7=[60 59 55 45 30]; 
% Y7=[18.4]; 
  
% 1 Input 1 Output 
% U1= [15]; 
% Y1=[8]; 
U2=[10]; 
Y2=[8.8]; 
U3=[3]; 
Y3=[9.6]; 
U4=[1.5]; 
Y4=[10.2]; 
U5=[1]; 
Y5=[10.7]; 
U6=[0.75]; 
Y6=[11.5]; 
U7=[0.5]; 
Y7=[18.4]; 
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YMat=[Y2',Y3',Y4',Y5',Y6',Y7']';  
Temp_Profile=[U2',U3',U4',U5',U6',U7']' 
ERR=[]; 
Yend_alltheta = YMat   
  
% initial condition for 1 temp value and 1st order 
X0 = zeros(2,1);        
% X0=[100;100]; 
PCECOEFS = [ones(2,1) X0]; 
i=0; 
  
while abs(minus(PCECOEFS(:,1),PCECOEFS(:,2)))> 1e-25*(ones(2,1)) 
    PCECOEFS(:,1)=PCECOEFS(:,2); 
OPTIONS=optimset('TolCon',1e-10,'TolFun',1e-10,'TolX',1e-
10,'display','iter','Maxiter',1000*1000,'MaxFunEvals',10000000); 
[PCEcoefs1, Fval] = 
fminsearch(@e_f_objPCE_firstorder_1temp_1st,PCECOEFS(:,2),OPTIONS, 
Temp_Profile, Yend_alltheta, 0) 
PCECOEFS(:,2)=PCEcoefs1; 
e_f_objPCE_firstorder_1temp_1st(PCEcoefs1, Temp_Profile, Yend_alltheta, 
1);  
i=i+1 
end 
 
function Error = e_f_objPCE_firstorder_1temp_1st(PCEcoef, Temp_Prof, 
Yend_alltheta, plotres); 
  [m,n] = size(Temp_Prof); 
  
PCE = zeros(m,1); 
  
for i = 1:m; 
   theta = Temp_Prof(i,:); 
   PCE(i) = e_f_PCE_firstorder_1temp_1st(theta, PCEcoef) 
end 
  
Error = sum((Yend_alltheta(:) - PCE(:)).^2) 
  
if plotres 
theta_val=[15]; 
Y_val_1=[8]; 
    v_end=size(theta_val) 
    for v=1:v_end(:,1) 
    Val_PCE_1(v)=e_f_PCE_secondorder_1temp_1st(theta_val(v,:), PCEcoef) 
    end 
     
set(gcf, 'PaperPositionMode', 'manual'); 
set(gcf, 'PaperUnits', 'inches'); 
set(gcf, 'PaperPosition', [0.25 2.5 5.6 6.0]); 
  
subplot(5,1,1:2) 
 axis([1,6,5,20]) 
    plot(Yend_alltheta,'ko','MarkerFaceColor','k') 
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    hold on 
    plot(PCE,'rd','MarkerFaceColor','r') 
    hold on 
     
    ylabel({'Dissolution Time'; 'Constant \tau 
(min)'},'fontsize',10,'fontweight','b') 
    leg=legend('Exp. data','PCE model','Location','Northwest') 
    legend boxoff  
    h=gca 
    h.XTick = [1,2,3,4,5,6]; 
    h.XTickLabel = {'1','2','3','4','5','6'}; 
     
    subplot(5,1,3) 
    axis([1,6,-30,30]) 
    h=stem((Yend_alltheta-PCE)./Yend_alltheta*100,'bx' ) 
    RES=(Yend_alltheta-PCE)./Yend_alltheta*100 
    ylabel('Residual %','fontsize',10,'fontweight','b') 
    xlabel('Data Points','fontsize',10,'fontweight','b') 
    leg2=legend('Training Points','Location','Northeast'); 
    hold on 
    legend boxoff   
     
    subplot(5,1,4:5) 
    axis([7,19,5,20]) 
 plot(Yend_alltheta,Yend_alltheta,'k--') 
 hold on 
 plot(Yend_alltheta,PCE,'rd','MarkerFaceColor','r') 
 hold on 
 plot(Y_val_1,Val_PCE_1,'gs','MarkerFaceColor','g') 
 hold on 
 plot(Y_val_1,Y_val_1,'bp','MarkerFaceColor','b') 
  
    xlabel('\tau from Experimental Data 
(min)','fontsize',10,'fontweight','b') 
    ylabel({'\tau from (5-1) PCE'; 'Model 
(min)'},'fontsize',10,'fontweight','b') 
    leg=legend({'Exp. 
data','PCE','Simulated','Actual'},'Position',[0.55 0.15 0.25 0.1]) 
    legend boxoff   
     
end 
       
disp(Yend_alltheta-PCE); 
disp((Yend_alltheta-PCE).^2); 
 
function [PCE, PCE_terms] = e_f_PCE_firstorder_1temp_1st(theta, c); 
PCE_order = 1; 
c = c(:)' ;%PCEcoefs 
n = length(theta); 
nc = length(c); 
Npce = 1; 
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for i = 1:PCE_order 
    Npce = Npce + factorial(n+i-1)/factorial(n-1)/factorial(i); 
end 
  
if nc ~=Npce 
   error('Wrong number of coefficients!') 
end 
PCE_terms(1) = 1; 
  
for i=1:n 
    PCE_terms(1+i) = theta(i); 
end 
  
PCE = sum(c.*PCE_terms); 
 
The optimization problem formulated to predict temperature profile is below. 
clc  
clear all 
close all 
% PCE using U1, U2, U3, U5, U6, U7 
% PCE_coeff=[-0.622753317044821;-
0.0149194088038712;0.0660550452915736;-
0.0108792025816413;0.512556063230387;-0.248755439386867;]; 
% Diss=[13.2]; 
x0=[1 60 52.5 45 37.5 30]'; 
Aeq=[1 0 0 0 0 0;0 1 0 0 0 0;0 0 0 0 0 1]; 
beq=[1;60;30]; 
A=[0 -1 1 0 0 0;0 0 -1 1 0 0;0 0 0 -1 1 0;0 0 0 0 -1 1]; 
b=[0;0;0;0]; 
ub=60; 
lb=1; 
x = fmincon(@hop,x0,A,b,Aeq,beq,lb,ub) 
 
function res = hop(x) 
%U7 is out  
PCE_coeff=[0.299121488098244;0.260627000123544;0.0644781150732125;0.036
4433813818839;0.104694900354823;-0.468268250553230;]; 
Diss=[18.4]; 
%U6 is out  
%PCE_coeff=[6.00308232535602;2.31027050440459;0.0644781144399137;0.0364
433832864824;0.504124282196730;-5.15711667024243;]; 
% Diss=[11.5]; 
%U5 is out  
% PCE_coeff=[-0.821840939171808;0.0443110978548544;0.0782818185241383;-
0.0694818767352390;0.601255156863062;-0.404404925722324;]; 
% Diss=[10.7]; 
%U4 is out  
% PCE_coeff=[-0.622753317044821;-
0.0149194088038712;0.0660550452915736;-
0.0108792025816413;0.512556063230387;-0.248755439386867;]; 
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% Diss=[10.2]; 
%U3 is out 
% PCE_coeff=[-1.43865838038008;0.147055654280234;0.102274182202390;-
0.0475870158806807;0.510654140628079;-0.547566095848332;]; 
% Diss=[9.6]; 
%U2 is out 
% PCE_coeff=[-0.466895454096701;-0.453160243278553;0.0703231297771442;-
0.00331632471156312;0.492199546171891;0.629343982713687;]; 
% Diss=[8.8]; 
%U1 is out 
% PCE_coeff=[-0.610241385049950;0.178718323684061;0.0634110776219363;-
0.00193391682608671;0.492199547265658;-0.618575668044410;]; 
% Diss=[8]; 
res=(((PCE_coeff'*x-Diss)/Diss)*100)^2 
end 
 VITA 
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